C-Terminally Extended P53 Activator Cross-Linking Peptidomimetic Macrocycles Against MDM2 / MDMX

Bridged peptidomimetic macrocycles with alkene or alkyne staples enhance p53 activation by improving binding to MDM2 and MDMX, addressing stability and off-target issues, offering a promising anti-cancer therapy.

JP2024544620APending Publication Date: 2024-12-03MERCK SHARP & DOHME LLC +2
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2024531589
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-29
Filing Date
2022-11-23
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Current small molecule inhibitors targeting the p53-MDM2/MDMX interaction show limited affinity and activity towards MDMX, leading to reduced efficacy in cancer therapy due to MDMX overexpression, and stapled peptides face challenges in stability, solubility, and off-target effects.

Method used

Development of bridged peptidomimetic macrocycles with alkene or alkyne staples and a polyamino acid C-terminal tail that enhance binding to MDM2 and MDMX, are protease-resistant, and cell-permeable, activating p53 intracellularly by antagonizing MDM2/MDMX binding.

Benefits of technology

The peptidomimetic macrocycles effectively activate p53, inhibit its degradation, and demonstrate improved binding, stability, and reduced off-target effects, making them suitable for anti-cancer therapy, especially in combination with chemotherapy and radiotherapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544620000001_ABST
    Figure 2024544620000001_ABST
Patent Text Reader

Abstract

The bridged peptidomimetic macrocycles disclosed herein contain an alkene or alkyne staple and a polyamino acid C-terminal tail. These bridged peptidomimetic macrocycles have improved binding to MDM2 and MDMX (also known as MDM4), are protease resistant, are cell permeable without inducing membrane disruption, and bind MDM2 and MDMX, thereby activating p53 intracellularly by antagonizing the binding of MDM2 and MDMX to p53. These peptidomimetic macrocycles may be useful in anti-cancer therapy, especially in combination with chemotherapy or radiation therapy.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] REFERENCE TO ELECTRONICALLY SUBMITTED SEQUENCE LISTING This application contains a Sequence Listing that has been submitted electronically in XML format and is incorporated herein by reference in its entirety. The XML file was created on October 3, 2022, is named 25345-WO-PCT-SEQLIST-03OCT2022.XML, and is 71,000 bytes in size on disk.

[0002] Disclosed herein are bridged peptidomimetic macrocycles with improved binding and / or physicochemical properties. These peptidomimetic macrocycles capable of binding mouse double minute 2 (MDM2, also known as E3 ubiquitin-protein ligase) and MDMX (also known as MDM4) can penetrate cells without inducing membrane disruption and can activate p53 intracellularly by binding MDM2 and MDMX, thereby antagonizing the binding of MDM2 and MDMX to p53. These macrocycles are potentially useful as anti-cancer therapies, particularly in combination with chemotherapy and / or radiation therapy. [Background technology]

[0003] The tumor suppressor protein p53 functions primarily as a DNA transcription factor. It is commonly repressed in cancer and plays a key role in protecting cells by inducing cell cycle arrest, apoptosis or senescence in response to various stress signals (Lane DP p53, guardian of the genome Nature. 1992 Jul 2;358(6381):15-6). Mechanisms that frequently result in p53 inactivation and tumorigenesis include increased expression of MDM2 and MDMX (also known as MDM4), negative regulators of p53. Both MDM2 and MDMX attenuate p53 function by directly interacting with p53 and preventing its interaction with related activators required for transcription, such as dTAFII and hTAFII. In addition, they are both E3 ligase components and target p53 for proteosome-mediated degradation. MDMX, unlike MDM2, does not have intrinsic E3 ubiquitin ligase activity. Instead, MDMX forms a heterodimeric complex with MDM2, thereby stimulating the ubiquitin activity of MDM2. As a result, p53 activity and protein levels are acutely suppressed by MDM2 and MDMX overexpression. Therefore, the development of inhibitors that disrupt the interaction of p53 with either MDM2 or MDMX, or both, is desirable, as they could prevent p53 degradation and restore p53-dependent transcriptional antitumor responses (Arni-Schmidt, O, M. Lokshin, and C. Prives. 2016. The roles of MDM2 and MDMX in cancer. Annu. Rev. Pathol. 11:617-644; Dongsheng Pei,1,2 Yanping Zhang,1,2 and Junnian Zheng1 Regulation of p53:a collaboration between MDM2 and MDMX. Oncotarget. 2012 Mar;3(3):228-235).

[0004] The structural interface of the p53-MDM2 / MDMX complex is characterized by an α-helix from the N-terminal transactivation domain of p53 that binds to a hydrophobic groove on the surface of the N-terminal domains of both MDM2 and MDMX. Three hydrophobic residues of p53, Phe19, Trp23, and Leu26, are key determinants of this interaction and protrude deeply into the MDM2 / MDMX interaction groove [see Figure 1]. The isolated p53 peptide is largely disordered and assumes an α-helical conformation upon binding. There are several examples of small molecules, peptides and biologics that mimic these interactions and compete for MDM2 / MDMX binding with p53 release (Tisato V1, Voltan R2, Gonelli A2, Secchiero P2, Zauli G2. MDM2 / X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer. J Hematol Oncol. 2017 Jul 3;10(1):133). However, the majority of developed small molecules show little affinity and activity for MDMX, which has some distinct structural differences in the p53 peptide binding groove compared to MDM2. Although several MDM2-specific molecules have entered first clinical trials, they mostly meet dose-limiting toxicities in patients (Tisato V1, Voltan R2, Gonelli A2, Secchiero P2, Zauli G2.MDM2 / X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.J Hematol Oncol.2017 Jul 3;10(1):133). It has been demonstrated that overexpression of MDMX in tumors attenuates the efficacy of MDM2-specific compounds, possibly through the maintenance of a heterodimeric complex of MDM2 and MDMX that inhibits and targets p53 for proteosomal degradation.MDM2-selective inhibitors could also induce higher levels of MDMX, highlighting the importance of simultaneously targeting both proteins to achieve efficient activation of p53 for achieving optimal therapeutic responses.

[0005] Protein-protein interactions (PPIs) are central to most biological processes and are often dysregulated in disease (Petta I., Lievens S., Libert C., Tavernier J., De Bosscher K. Modulation of Protein-Protein Interactions for the Development of Novel Therapeutics. Mol. Ther. 2015;24:707-718; Macalino SJY, Basith S., Clavio NAB, Chang H., Kang S., Choi S. Evolution of In Silico Strategies for Protein-Protein Interaction Drug Discovery. Molecules. 2018;23:1963). Therefore, PPIs are attractive therapeutic targets for novel drug discovery. However, in contrast to the deep protein cavities that typically accommodate small molecules, PPI surfaces are generally large and flat, which limits success in developing small molecule inhibitors that target PPIs (Scott, DE, Bayly, AR, Abell, C. and Skidmore, J. (2016) Small molecules, big targets: drug discovery faces the protein-protein interaction challenge. Nat. Rev. Drug Discov. 15, 533-550). The realization that 40% of all PPIs are mediated by relatively short peptide motifs has raised the possibility of developing peptide-based inhibitors that orthosterically compete for the interface between the ligand-target cognate partners (Nevola L, Giralt E. Modulating protein-protein interactions: the potential of peptides. Chem Commun.2015;51:3302-15). When removed from the context of a protein ligand, such peptides are often unstructured and intrinsically disordered, but can achieve their biologically relevant conformation upon binding to a protein target (Nevola L, Giralt E. Modulating protein-protein interactions: the potential of peptides. Chem Commun. 2015;51:3302-15). However, for intracellular targets, peptide modalities can be challenged by proteolytic susceptibility, low conformational stability (resulting in weak affinity and off-target effects), and poor cell permeability, further limiting the implementation of intracellular targeting and / or oral bioavailability (Lau, JL; Dunn, M.K. Therapeutic peptides: Historical perspectives, current development trends, and future directions Bioorg.Med.Chem. 2017, 26, 2700-2707; Fosgerau, K.; Hoffmann, T. Peptide therapeutics: current status and future directions Drug Discovery Today 2015, 20, 122-128; Bakail M., Ochsenbein F. Targeting protein-protein interactions, a wide open field for drug design. Comptes Rendus Chimie. 2016, 19, 19-27; A. Henninot, JC Collins, JM Nuss. The current state of peptide drug discovery: back to the future J.Med.Chem.,61(2018),pp.1382-1414;Morrison C.,Constrained peptides' time to shine?.Nature Reviews Drug Discovery volume 17, pp.531-533(2018);Valeur E.,et al.New Modalities for Challenging Targets in Drug Discovery.Angew.Chem.Int.Ed.2017,56,10294-10323;Cary,D.R.;Ohuchi,M.;Reid,P.C.;Masuya,K.Constrained Peptides in Drug Discovery and Development.Yuki Gosei Kagaku Kyokaishi 2017,75,1171-1178)。.

[0006] To address these issues, several strategies have been pursued, including macrocyclization and modification of the peptide backbone to obtain molecules with improved activity and pharmacokinetic properties, as well as constraining the peptide into its biologically plausible conformation to bind to its target (Lau, JL; Dunn, MK Therapeutic peptides: Historical perspectives, current development trends, and future directions Bioorg. Med. Chem. 2017, 26, 2700-2707; Fosgerau, K.; Hoffmann, T. Peptide therapeutics: current status and future directions Drug Discovery Today 2015, 20, 122-128; Bakail M., Ochsenbein F. Targeting protein-protein interactions, a wide open field for drug design. Comptes Rendus Chimie. 2016, 19, 19-27; A. Henninot, JC Collins, JM Nuss. The current state of peptide drug discovery: back to the future J.Med.Chem.,61(2018),pp.1382-1414;Morrison C.,Constrained peptides' time to shine?Nature Reviews Drug Discovery volume 17,pp.531-533(2018);Valeur E.,et al.New Modalities for Challenging Targets in Drug Discovery.Angew.Chem.Int.Ed.2017,56,10294-10323;Cary,DR;Ohuchi,M.;Reid,PC;Masuya,K.Constrained Peptides in Drug Discovery and Development.Yuki Gosei Kagaku Kyokaishi 2017,75,1171-1178; Vinogradov A., Macrocyclic Peptides as Drug Candidates: Recent Progress and Remaining Challenges. J. Am. Chem. Soc., 2019,141(10),pp 4167-4181; Sawyer, TK Macrocyclic α helical peptide therapeutic modality: A perspective of learnings and challenges. Bioorg. Med. Chem. 2018,26,2807-2815). First, by biasing peptides towards their bound conformation, the entropy penalty upon binding is reduced, thus improving the binding constant as well as possibly reducing the chance of undesired off-target effects. Second, macrocyclization may confer various degrees of proteolysis resistance by modifying key backbone and / or side chain structural moieties in the peptide. Third, macrocyclization may enhance cell permeability, for example, by increasing the stability of intramolecular hydrogen bonds to reduce the desolvation penalty that arises in the transport of peptides across otherwise non-polar cell membranes. Among the several cyclization techniques described, stapling by metathesis using non-proteinogenic amino acids, such as alpha-methylalkenyl side chains, has proven effective, especially when the desired secondary structure of the peptide macrocycle is helical (Sawyer, TK Macrocyclic α helical peptide therapeutic modality: A perspective of learnings and challenges. Bioorg. Med. Chem. 2018, 26, 2807-2815; LD Walensky, GH Bird Hydrocarbon-stapled peptides: principles, practice, and progress J Med Chem, 57(2014), pp.6275-6288; YS Tan, DPLane, CSVerma Stapled peptide design: principles and roles of computation Drug Discov Today,21(2016),pp.1642-1653;Ali AM.,et al.Stapled Peptides Inhibitors:A New Window for Target Drug Discovery.Computational and Structural Biotechnology Journal,2019,17,263-281;Klein M.,Stabilized helical peptides:overview of the technologies and its impact on drug discovery.Expert Opinion on Drug Discovery.2017,12,1117-1125;Lerge J et al.Stapled peptides as a new technology to investigate protein-protein interactions in human platelets.Chem Sci,2108,9,4638-4643). Stapling requires the incorporation of appropriate unnatural amino acid precursors that are placed at appropriate positions along the peptide sequence so as not to interfere with the binding surface of the helix. Linkers can be of different types and span different lengths, resulting in i,i+3, i,i+4 or i,i+7 staples. They have been used primarily to stabilize helical conformations, but recent studies have also applied ring-closing metathesis (RCM) strategies to non-helical peptides (Xu W., Macrocyclized Extended Peptides: Inhibiting the Substrate-Recognition Domain of Tankyrase. J. Am. Chem. Soc., 2017, 139(6), pp 2245-2256; Wiedmann, M. M., et al.Development of Cell-Permeable,Non-Helical Constrained Peptides to Target a Key Protein-Protein Interaction in Ovarian Cancer.Angew.Chem.Int.Ed.2017,56,524-529)。.

[0007] BCL-2 Liquid-BH3 Liquids (LDWalensky,ALKung,I.Escher,TJM). alia,S.Barbuto,RDWright,G.Wagner,GLVerdineandSJKorsmeyer.Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix.Science,2004,305,1466-1470;SAKawamoto, A. Coleska, X. Ran, H. Yi, CYYang and S. Wang CLL / lymphoma 9(BCL9)protein-protein interaction,J.Med.Chem.,2012,55,1137-1146; Zhu, GHBird, K. Sukhdeo, J.-J. Zhao, M. Mani, M. Lemieux, DECarrasco, J. Ryan;D.Horst,M.Fulciniti,NCMunshi,W.Xu,ALKung,RAShivdasani,LDWalensky,andDRCarrasco inhibits oncogenic Wnt signaling.Sci.Transl.Med.,2012,4,148ra117)、β-カテン-TCF(L Dietrich,B Rathmer,K Ewan,T Bange,S Heinrichs,TC Dale,D Schade,TN Grossmann.Cell permeable stapled peptide inhibitor of Wnt signaling that targets β-catenin protein-protein interactions.Cell Chem.Biol.,24,958-968(2017)), Rab-GTPase-effector (Spiegel J,Cromm PM,Itzen A,Goody RS,Grossmann TN,Waldmann H.Direct targeting of Rab-GTPase-effector interactions.Angew Chem Int Ed Engl.2014 Feb 24;53(9):2498-503), ERα-coactivator proteins (Xie M.,et al.Structural Basis of Inhibition of ERα-Coactivator Interaction by High-Affinity N-Terminus Isoaspartic Acid Tethered Helical Peptides.J.Med.Chem.,2017,60(21),pp 8731-8740), Cullin3-BTB (Paola de.,et al.Cullin3-BTB interface: a novel target for stapled peptides.PLoS One.2015 Apr 7;10(4):e0121149), VDR-coactivator protein (Misawa T.,et al.Structural development of stapled short helical peptides as vitamin D receptor(VDR)-coactivator interaction inhibitors.Bioorg Med Chem.2015 Mar 1;23(5):1055-61), eIf4E (Lama D.,et al,Structural insights reveal a recognition feature for tailoring hydrocarbon stapled-peptides against the eukaryotic translation initiation factor 4E protein.Chemical Science.2019,10,2489-2500), ATSP-7041 [see International Publication No. 2013123266, SAH-p53-8 [Bernal et al.,Cancer Cell 18:411-422(2010)] and p53-MDM2 / MDMX(F.Bernal,AFTyler,SJKorsmeyer,LDWalensky,and GLVerdine.Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide.J.Am.Chem.Soc.,2007,129,2456-2457;LKHenchey,JRPorter,I Ghosh and PSArora complex.Chembiochem.,2010,11,2104-2107;CJBrown,ST,Quah,JJong,AMGoh,PC,Chiam,KHKhoo,MLHoong,MALee,L.Yurlova,KZolghadr,TLJoseph,CSVerma; that activate p53.ACS Chem.Biol.,2013,8,506-512;YSChang,B.Graves,V.Guerlavais,C.Tovar,K.Packman,T.To,K.Olson,K.Kesavan,P.Gangurde,A.Mukherjee,T.Baker,K.Darlak,C.Elkin,Z.Filipovic,FZ Qureshi, H. Cai, P. Berry, E. Feyfant, XEShi, J. Horstick, A. Annis, N. Fotouhi, T. Manning, H. Nash, LTVassilev and TKSawyer.Stapled a-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc. Natl. Acad. Sci. USA, 2013, 110, E3445-E3455).

[0008] For p53-MDM2 / MDMX, ALRN-6924 (Aileron Therapeutics, Inc.), a dual selective stapled peptide, has progressed into phase II clinical trials (A. Burgess, KM Chia, S. Haupt, D. Thomas, Y. Haupt and E. Lim. Clinical overview of MDM2 / X targeted therapies. Front. Oncol., 2016, 6, 1-7; K. Kojima, J. Ishizawa and M. Andreeff. Pharmacological activation of wild-type p53 in the therapy of leukemia. Exp. Hematol., 2016, 44, 791-798; V. Tisato, R. Voltan, A. Gonelli, P. Secchiero and G. Zauli. MDM2 / X inhibitors under clinical evaluation: Perspectives for the management of hematological malignancies and pediatric cancer. J. Hematol. Oncol., 2017, 10, 133). All-D α-amino acid stapled peptides have also been reported to provide additional resistance to protease-mediated degradation (Aronia, Pietro et al. P53 activator peptidomimetic macrocycles, WO 2020 / 257153).

[0009] Although the example of ALRN-6924 has encouraged the advancement of stapled peptides into the clinic, challenges remain. Among these, engineering the correct set of binding elements and physicochemical properties in the molecule to provide optimal stability, solubility and cellular activity is desirable to minimize the dose required for administration to patients. Furthermore, engineering this set of binding elements and physicochemical properties to minimize off-target activity is also desirable to reduce the risk of off-target related adverse events to patients. The peptidomimetic macrocycles disclosed herein address these challenges and provide unexpected properties. [Prior art documents] [Patent documents]

[0010] [Patent Document 1] International Publication No. 2013123266 [Patent Document 2] International Publication No. 2020 / 257153 [Non-patent literature]

[0011] [Non-Patent Document 1] Lane DP p53,guardian of the genome Nature.1992 Jul 2;358(6381):15-6 Arni-Schmidt, O, M.Lokshin, and C.Prives.2016.The roles of MDM2 and MDMX in cancer.Annu.Rev.Pathol.11:617-644 [Non-Patent Document 2] Dongsheng Pei, 1,2 Yanping Zhang, 1,2 and Junnian Zheng1 Regulation of p53:a collaboration between MDM2 and MDMX.Oncotarget.2012 Mar;3(3):228-235 [Non-Patent Document 3] Tisato V1、Voltan R2、Gonelli A2、Secchiero P2、Zauli G2.MDM2 / X inhibitors under clinical evaluation:perspectives for the management of hematological malignancies and pediatric cancer.J Hematol Oncol.2017 Jul 3;10(1):133

Outdoor Tools 4

Direct Environment 5

Outdoor Configuration 6

Direct Environment 7

Non-licensed Document 14

Non-licensed Document 15

Non-licensed Document 16

Non-licensed Document 17

Non-licensed Document 18

Non-licensed Document 19

Direct Entries 25

Direct Entries 26

Direct Accounts 27

Non-Patent Document 37

Non-Patent Document 38

Non-Patent Document 39

Summary of the Invention

[0012] The bridged peptidomimetic macrocycles disclosed herein contain an alkene or alkyne staple and a polyamino acid C-terminal tail. These bridged peptidomimetic macrocycles have improved binding to MDM2 and MDMX (also known as MDM4), are protease resistant, are cell permeable without inducing membrane disruption, and activate p53 intracellularly by binding MDM2 and MDMX, thereby antagonizing the binding of MDM2 and MDMX to p53. These peptidomimetic macrocycles may be useful in anti-cancer therapy, particularly in combination with chemotherapy and / or radiation therapy. [Brief description of the drawings]

[0013] [Figure 1] Crystal structure of the p53-MDM2 (Protein Data Bank (PDB) ID: 1YCR) complex (Baek et al., JACS 134:103-106 92012). MDM2 is shown as a surface and the bound peptide is shown as a cartoon with interacting residues L-Phe19, L-Trp23, and L-Leu26 highlighted as sticks. Hydrogen bond interactions are shown as dotted lines. [Diagram 2] FIG. 1 is a helical wheel representing azido-ATSP-7041 with a 6xA tail (SEQ ID NO: 28), drawn according to https: / / www.biorxiv.org / content / 10.1101 / 416347v1. The figure discloses SEQ ID NOs: 27-28, respectively, in order of appearance. [Diagram 3] Snapshots of the conformation of ATSP-7041 with the AAFAAF tail (SEQ ID NO: 16)-MDM2 complex sampled during molecular dynamics simulations. MDM2 is shown as a surface / cartoon and the bound peptide is shown as a cartoon with the C-terminal residues Phe14 and Phe17 highlighted and the hydrocarbon staple linker shown as a stick connected above the helix. [Figure 4]Snapshots of the conformation of ATSP-7041 with AEAAAa tail (SEQ ID NO: 17)-MDM2 complex sampled during molecular dynamics simulation. MDM2 is shown as a surface / cartoon and the bound peptide is shown in cartoon form highlighting the interaction between Glu14 (salmon) and Mdm2 Arg97 (blue) side chains. The hydrocarbon staple linker is shown as a stick connected above the helix. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] The bridged peptidomimetic macrocycle disclosed herein is derived from a peptidomimetic analog of a portion of the human p53 protein and has the formula (I): R 1 -R 2 -Beta-Ala-LTFX 1 -EYWAQR 3 -X 2 -Z 1 -Z 2 -Z 3 -Z 4 -Z 5 -Z 6 -R 4 (SEQ ID NO: 18) (I), wherein: R 1 is acyl and C 1-12 alkyl, R 2 is a natural or unnatural L-amino acid residue, R 3 is an aliphatic natural or unnatural amino acid residue, R 4 -OH, -NH 2 and 1 to 3 L- or D-amino acid residues, where the C-terminal tail is an acid or amide group; X 1 and X 2 each is independently an α-mono- or α,α-disubstituted non-natural L- or D-amino acid residue; 1 and X 2are bridged via hydrocarbon bonds from their respective alpha carbons, Z 1 , Z 2 , Z 3 , Z 4 , Z 5 and Z 6 Each of is independently a natural or unnatural amino acid residue.

[0015] In one embodiment, R 1 is acyl. In one embodiment, R 1 is acetyl.

[0016] In one embodiment, R 1 is C 1-12 In one embodiment, R 1 is C 1-4 It is an alkyl.

[0017] In one embodiment, R 2 is selected from a lysine residue, an azidolysine residue and a threonine residue.

[0018] In one embodiment, R 3 is selected from leucine and cyclobutylalanine residues.

[0019] In one embodiment, R 4 -OH and -NH 2 is selected from.

[0020] In one embodiment, R 4 is selected from 1 to 3 L- or D-amino acid residues with an amide C-terminal tail.

[0021] In one embodiment, R 4 is -NH 2 and the C-terminal tail is selected from an L- or D-amino acid residue which is an amide.

[0022] In one embodiment, R 4 Ha-NH 2 It is.

[0023] In one embodiment, X 1 and X 2 Each of X is independently an α-monosubstituted or α,α-disubstituted non-natural L- or D-amino acid residue. 1 and X 2 are bridged from their respective alpha carbons through a hydrocarbon bond selected from an alkene and a dialkyne. In one embodiment, the bond is an alkene bond. In one embodiment, the bond is a dialkyne bond.

[0024] In one embodiment, X 1 and X 2 Each of X is independently selected from the residues of (R)-2-amino-2-methyldec-9-enoic acid and (S)-2-amino-2-methylhept-6-enoic acid. 1 and X 2 are bridged from their respective alpha carbons via alkene bonds.

[0025] In one embodiment, X 1 and X 2 Each of X is independently selected from the group consisting of (R)-2-amino-2-methyloct-7-ynoic acid and (S)-2-amino-2-methylhept-6-ynoic acid. 1 and X 2 are cross-linked from their respective alpha carbons via dialkyne bonds.

[0026] In one embodiment, Z 1 , Z 2 , Z 4 , and Z 5 Each of Z is independently a natural or unnatural amino acid residue. 3 and Z 6 Each of Z is independently an alkyl or aromatic amino acid residue. 3 and Z 6 is a phenylalanine residue.

[0027] In one embodiment, Z 1 , Z 2, Z 3 , Z 4 , Z 5 and Z 6 One or more of are independently a natural or unnatural L- or D-negatively charged amino acid residue.

[0028] In one embodiment, Z 1 is selected from glutamic acid and gamma-carboxyglutamic acid (Gla) residues.

[0029] In one embodiment, Z 3 is a glutamic acid residue.

[0030] In one embodiment, Z 5 is an alpha-methylglutamic acid residue.

[0031] In one embodiment, Z 1 -Z 2 -Z 3 -Z 4 -Z 5 -Z 6 The sequences are selected from AAFAAF (SEQ ID NO: 16), AAFA(alpha-Me-Glu)F (SEQ ID NO: 19), AAEAA(D-Ala) (SEQ ID NO: 20), EAFAAF (SEQ ID NO: 21), AAAAAA (SEQ ID NO: 28) and AAAAA(D-Ala) (SEQ ID NO: 22).

[0032] In one embodiment, Z 1 -Z 2 -Z 3 -Z 4 -Z 5 -Z 6 The sequence is selected from AAFAAF (SEQ ID NO: 16), AAFA(alpha-Me-Glu)F (SEQ ID NO: 19), EAFAAF (SEQ ID NO: 21) and AAAAA(D-Ala) (SEQ ID NO: 22).

[0033] In one embodiment of the bridged peptidomimetic macrocycle of formula (I): R 1 is acetyl, R 2is selected from a lysine residue and an azidolysine residue; R 3 is a cyclobutylalanine residue, R 4 is -NH 2 and X 1 and X 2 each is independently an α-mono- or α,α-disubstituted non-natural L- or D-amino acid residue; 1 and X 2 are bridged from their respective alpha carbons via alkene or dialkyne hydrocarbon bonds, Z 1 -Z 2 -Z 3 -Z 4 -Z 5 -Z 6 The sequences are selected from AAFAAF (SEQ ID NO: 16), AAFA(alpha-Me-Glu)F (SEQ ID NO: 19), AAEAA(D-Ala) (SEQ ID NO: 20), EAFAAF (SEQ ID NO: 21), AAAAAA (SEQ ID NO: 28) and AAAAA(D-Ala) (SEQ ID NO: 22).

[0034] In one embodiment of the bridged peptidomimetic macrocycle of formula (I): R 1 is acetyl, R 2 is selected from a lysine residue and an azidolysine residue; R 3 is a cyclobutylalanine residue, R 4 is -NH 2 and X 1 and X 2 is independently selected from the residues of (R)-2-amino-2-methyldec-9-enoic acid and (S)-2-amino-2-methylhept-6-enoic acid; 1 and X 2 are bridged from their respective alpha carbons via alkene bonds, Z 1 -Z 2 -Z3 -Z 4 -Z 5 -Z 6 The sequence is selected from AAFAAF (SEQ ID NO: 16), AAFA(alpha-Me-Glu)F (SEQ ID NO: 19), EAFAAF (SEQ ID NO: 21) and AAAAA(D-Ala) (SEQ ID NO: 22).

[0035] In one embodiment of the bridged peptidomimetic macrocycle of formula (I): R 1 is acetyl, R 2 is selected from a lysine residue and an azidolysine residue; R 3 is a cyclobutylalanine residue, R 4 is -NH 2 and X 1 and X 2 is independently selected from the group consisting of (R)-2-amino-2-methyloct-7-ynoic acid and (S)-2-amino-2-methylhept-6-ynoic acid; 1 and X 2 are bridged from their respective alpha carbons via dialkyne bonds, Z 1 -Z 2 -Z 3 -Z 4 -Z 5 -Z 6 The sequence is selected from AAFAAF (SEQ ID NO: 16), AAFA(alpha-Me-Glu)F (SEQ ID NO: 19), EAFAAF (SEQ ID NO: 21) and AAAAA(D-Ala) (SEQ ID NO: 22).

[0036] The Z 1 -Z 2 -Z 3 -Z 4 -Z 5 -Z 6 The sequence may improve binding to MDM2 and / or MDMX. 1 -Z 2 -Z 3 -Z4 -Z 5 -Z 6 The sequences are modified to further improve cellular activity in a p53 cellular reporter gene assay.

[0037] The bridged peptidomimetic macrocycles disclosed herein bind MDM2 and MDMX, are cell-permeable without inducing detectable damage to the cell membrane, and activate p53 intracellularly. They interfere with the binding of p53 to MDM2 and / or p53 to MDMX, thereby releasing functional p53 and inhibiting its destruction.

[0038] The bridged peptidomimetic macrocycles described herein may be useful for treating cancers and other disorders characterized by undesirable low levels or activity of p53 and / or for treating cancers and other disorders characterized by undesirable high levels of activity of MDM2 or MDMX. They may also be useful for treating conditions of inappropriate cell cycle arrest and apoptosis, such as disorders associated with deregulation of the p53 transcription pathway leading to conditions of excessive cell survival and proliferation, such as cancer and autoimmunity, as well as neurodegeneration and immune disorders.

[0039] These bridged peptidomimetic macrocycles contain two modified amino acids that together form an intramolecular bridge that stabilizes the alpha-helical secondary structure of a portion of the peptide that antagonizes the binding of p53 to MDM2 and / or MDMX. The bridge is called a "staple" and the bridged peptide is called a "staple peptide."

[0040] In one embodiment of the bridged peptidomimetic macrocycle, X 1 or X 2Each α-mono- or α,α-disubstituted amino acid residue at position 1 contains one or two α-carbon-bonded reactive groups, and the reactive group of a first α-mono- or α,α-disubstituted amino acid residue can react with the reactive group of a second α-mono- or α,α-disubstituted amino acid residue to form a crosslinker. In one embodiment, the reactive group comprises a terminal olefinic group. In another embodiment, the reactive group comprises a terminal alkyne group.

[0041] In one embodiment of the bridged peptidomimetic macrocycle, the unnatural amino acid residue is at position X 1 is an (R)-2-amino-2-methyldec-9-enoic acid residue, and position X 2 is the (S)-2-amino-2-methylhept-6-enoic acid residue, and the staple is an olefin obtained by ring-closing metathesis.

[0042] In one embodiment of the bridged peptidomimetic macrocycle, the unnatural amino acid is at position X 1 is an (R)-2-amino-2-methyloct-7-ynoic acid residue, and position X 2 is the (S)-2-amino-2-methylhept-6-ynoic acid residue, and the staple is an olefin obtained by Graeser coupling.

[0043] In one embodiment, the bridged peptidomimetic macrocycle has formula (IV): [ka] It includes the amino acid sequence shown in SEQ ID NO:4.

[0044] In one embodiment, the bridged peptidomimetic macrocycle has formula (IX): [ka] It includes the amino acid sequence shown in SEQ ID NO: 9.

[0045] In one embodiment, the bridged peptidomimetic macrocycle has formula (X): [ka] The amino acid sequence shown in SEQ ID NO: 10 is represented by the formula:

[0046] In one embodiment, the bridged peptidomimetic macrocycle has formula (XIII): [ka] It includes the amino acid sequence shown in SEQ ID NO: 13.

[0047] In one embodiment, the bridged peptidomimetic macrocycle binds both MDM2 and MDMX, is cell-permeable without detectable cell membrane disruption as measured by a lactate dehydrogenase (LDH) release assay, and activates p53 intracellularly.

[0048] In one embodiment, the bridged peptidomimetic macrocycle binds both MDM2 and MDMX, activates p53 intracellularly, and is selective in counterscreening assays.

[0049] In one embodiment, the bridged peptidomimetic macrocycle binds both MDM2 and MDMX, is cell permeable without detectable cell membrane disruption as measured by lactate dehydrogenase (LDH) release assay, activates p53 intracellularly, and is selective in counterscreening assays.

[0050] The amino acid sequences of reference macrocycle 1 (SEQ ID NO: 1) and macrocycles 2-13 (SEQ ID NOs: 2-13) are listed in Table 1. [Table 1] Also disclosed herein are methods of modulating p53 and / or MDM2 and / or MDMX activity in a subject comprising administering to the subject a bridged peptidomimetic macrocycle of structural formula (I), which comprises any one of the aforementioned peptidomimetic macrocycles.

[0051] Further disclosed herein is a method of antagonizing the interaction between p53 and MDM2 and / or between p53 and MDMX in a subject comprising administering to the subject a bridged peptidomimetic macrocycle of structural formula (I), which comprises any one of the aforementioned peptidomimetic macrocycles.

[0052] Further disclosed herein are bridged peptidomimetic macrocycles of structural formula (I) comprising any one of the aforementioned peptidomimetic macrocycles for the treatment of cancer. For example, a method for treating cancer in a subject having cancer comprises administering any one of the aforementioned bridged peptidomimetic macrocycles to the subject.

[0053] In one embodiment, the cancer is selected from melanoma, non-small cell lung cancer, head and neck cancer, urothelial cancer, breast cancer, gastrointestinal cancer, multiple myeloma, hepatocellular carcinoma, non-Hodgkin's lymphoma, renal cancer, Hodgkin's lymphoma, mesothelioma, ovarian cancer, small cell lung cancer, esophageal cancer, anal cancer, biliary tract cancer, colorectal cancer, cervical cancer, thyroid cancer, salivary gland cancer, pancreatic cancer, bronchial cancer, prostate cancer, pancreatic cancer, gastric cancer, ovarian cancer, bladder cancer, brain or central nervous system cancer, peripheral nervous system cancer, uterine or endometrial cancer, oral cavity or pharynx cancer, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, small intestine or appendix cancer, adrenal gland cancer, osteosarcoma, chondrosarcoma, and cancer of the blood tissue.

[0054] Further disclosed herein is a combination therapy for treating cancer, comprising administering to a subject a therapeutically effective amount of a bridged peptidomimetic macrocycle of structural formula (I) comprising any one of the aforementioned peptidomimetic macrocycles, and a therapeutically effective amount of a chemotherapeutic agent or radiation. In one embodiment, the chemotherapeutic agent or radiation is administered to the subject followed by the peptidomimetic macrocycle, the peptidomimetic macrocycle is administered to the subject followed by the chemotherapeutic agent or radiation, or the chemotherapeutic agent or radiation is administered to the subject simultaneously with administration of the peptidomimetic macrocycle. Thus, in one embodiment, the combination therapy for treating cancer comprises a therapeutically effective amount of a bridged peptidomimetic macrocycle of any one of the aforementioned peptidomimetic macrocycles, and a therapeutic dose of a chemotherapeutic agent or radiation.

[0055] In one embodiment, a combination therapy for treating cancer comprises administering to a subject a therapeutically effective amount of a bridged peptidomimetic macrocycle of structural formula (I), comprising any one of the peptidomimetic macrocycles described above, and a therapeutically effective amount of a checkpoint inhibitor. In certain aspects, the checkpoint inhibitor is an anti-PD1 antibody or an anti-PD-L1 antibody. In further aspects, the treatment further comprises administering to the subject a therapeutically effective dose of a chemotherapeutic agent or radiation.

[0056] In one embodiment, the treatment of cancer comprises administering to a subject having cancer a vector comprising a nucleic acid molecule encoding a wild-type p53 protein or a p53 variant having transcriptional activation activity, followed by one or more administrations of a therapeutically effective amount of a bridged peptidomimetic macrocycle of structural formula (I) comprising any one of the aforementioned peptidomimetic macrocycles. In one embodiment, the vector is a plasmid, a retrovirus, an adenovirus, or an adeno-associated virus. In one embodiment, chemotherapy or radiation therapy is administered to the subject prior to administering the vector to the subject or after administering the vector to the subject. In one embodiment, the therapy comprises administering a checkpoint inhibitor to the subject prior to administering the vector to the subject or after administering the vector to the subject. The checkpoint inhibitor may be administered prior to administering chemotherapy or radiation therapy to the subject or after administering chemotherapy or radiation therapy to the subject.

[0057] In one embodiment, the chemotherapeutic agent is actinomycin, all-trans retinoic acid, alitretinoin, azacitidine, azathioprine, bexarotene, bleomycin, bortezomib, carmoful, carboplatin, capecitabine, cisplatin, chlorambucil, cyclophosphamide, cytarabine, dacarbazine, daunorubicin, docetaxel, doxifluridine, doxorubicin, epirubicin, epothilone, etoposide, fluorouracil, gemcitabine, hydroxyurea, isoflurane, ribavirin ... Selected from darubicin, imatinib, ixabepilone, irinotecan, mechlorethamine, melphalan, mercaptopurine, methotrexate, mitoxantrone, nitrosourea, oxaliplatin, paclitaxel, pemetrexed, romidopsin, tegafur, temozolomide (oral dacarbazine), teniposide, thioguanine, topotecan, utiderone, valrubicin, vemurafenib, vinblastine, vincristine, vindesine, vinorelbine, and vorinostat.

[0058] In one embodiment, disclosed herein is a pharmaceutical composition comprising any one of the aforementioned peptidomimetic macrocycles and a pharma- ceutically acceptable carrier or excipient. In one embodiment, the peptidomimetic macrocycle is selected from SEQ ID NO:4, SEQ ID NO:9, SEQ ID NO:10, and SEQ ID NO:13.

[0059] definition "Acyl" refers to a class of organic radicals, RCO-, formed by removal of a hydroxyl group from a carboxylic acid. In one embodiment, R is C 1-12 In one embodiment, R is C 1-4 R is alkyl. In one embodiment, the acyl is acetyl (i.e., R is methyl).

[0060] "Administer" and "administering" are used to mean introducing at least one peptidomimetic macrocycle, or a pharmaceutical composition comprising at least one peptidomimetic macrocycle, into a subject. When administration is for therapeutic purposes, the substance is provided at or after diagnosis of abnormal cell growth, such as a tumor. Therapeutic administration of the substance serves to inhibit tumor cell growth or abnormal cell growth.

[0061] "Alkyl" means an alkyl group containing 1 to 18 carbon atoms (C 1-18 alkyl), more specifically, alkyl having 1 to 12 carbon atoms (C 1-12 alkyl), or even more specifically, 1 to 4 carbon atoms (C 1-4 In one embodiment, alkyl is methyl.

[0062] The term "α-amino acid" or simply "amino acid" refers to a molecule that contains both an amino group attached to a side chain (the R group) and a hydrogen atom, and a carboxyl group attached to a carbon referred to as the α-carbon, and has the formula shown for (R) and (S) α-amino acids: [ka] It can be represented by:

[0063] Generally, L-amino acids have the (S) configuration, with the exception of cysteine, which has the (R) configuration, and glycine, which is achiral. α-Amino acids suitable for the all-D peptides disclosed herein include only the D-isomers of the natural amino acids and their analogs, as well as unnatural amino acids prepared by organic synthesis or other metabolic routes (excluding α,α-disubstituted amino acids, which may be L, D or achiral). Unless the context specifically indicates otherwise, the term amino acid, as used herein, is intended to include amino acid analogs. As used herein, D-amino acids are designated by the superscript "D" (e.g., DLeu), and L amino acids are designated with an "L" (e.g., L-Leu) or without the L identifier (e.g., Leu).

[0064] The term "α,α-disubstituted amino acid" refers to a molecule or moiety that contains both an amino group and a carboxyl group attached to an α-carbon that is attached to two natural or unnatural amino acid side chains, or a combination thereof. Exemplary α,α-disubstituted amino acids are shown below. These α,α-disubstituted amino acids contain a side chain with a terminal olefin reactive group. [ka] "Amino acid analog" or "unnatural amino acid" refers to a molecule that is structurally similar to an amino acid and can substitute for an amino acid in the formation of a peptidomimetic macrocycle. Amino acid analogs include, but are not limited to, compounds that are structurally identical to the amino acids defined herein, except for the inclusion of one or more additional methylene groups between the amino and carboxyl groups (e.g., α-amino, β-carboxy acids), or replacement of the amino or carboxy group with a similarly reactive group (e.g., replacement of a primary amine with a secondary or tertiary amine, or replacement of a carboxy group with an ester).

[0065] "Amino acid side chain" refers to the moiety attached to the α-carbon in an amino acid. For example, the amino acid side chain of alanine is methyl, the amino acid side chain of phenylalanine is phenylmethyl, the amino acid side chain of cysteine ​​is thiomethyl, the amino acid side chain of aspartic acid is carboxymethyl, the amino acid side chain of tyrosine is 4-hydroxyphenylmethyl, etc. Other non-natural amino acid side chains include those that occur naturally (e.g., amino acid metabolites) or are synthetically produced (e.g., α,α-disubstituted amino acids), for example.

[0066] "Blocking group" refers to a chemical moiety present at either the carboxy- or amino-terminus of the polypeptide chain of a subject peptidomimetic macrocycle. Blocking groups at the carboxy-terminus include unmodified carboxylic acids (i.e., -COOH) or carboxylic acids bearing a substituent. For example, the carboxy-terminus can be substituted with an amino group to yield a carboxamide at the C-terminus (i.e., -CONH 2 ). Various substituents include, but are not limited to, primary and secondary amines, including pegylated secondary amines. Blocking groups for the amino terminus include unmodified amines (i.e., -NH 2 ), or amines bearing substituents. For example, the amino terminus can be substituted with an acyl group to give a carboxamide at the N-terminus. Various substituents include, but are not limited to, C 1 -C 6 Carbonyl, C 7 -C 30 Included are carbonyl and substituted acyl groups, including pegylated carbamates.

[0067] "Co-administration" means that at least two different biologically active compounds are each administered to a subject during a time frame in which their respective periods of biological activity overlap. Thus, the term includes co-extensive administration as well as sequential administration. When co-administration is used, the route of administration does not have to be the same. Biologically active compounds include peptidomimetic macrocycles, as well as other compounds useful in the treatment of cancer, such as, but not limited to, agents such as vinca alkaloids, nucleic acid inhibitors, platinum agents, interleukin-2, interferons, alkylating agents, antimetabolites, corticosteroids, DNA intercalators, anthracyclines, and ureas. In addition to those exemplified herein, examples of specific agents include hydroxyurea, 5-fluorouracil, anthramycin, asparaginase, bleomycin, dactinomycin, dacabazine, cytarabine, busulfan, thiotepa, lomustine, mechlorethamine, cyclophosphamide, melphalan, mechlorethamine, chlorambucil, carmustine, 6-thioguanine, methotrexate, etc. One of skill in the art will understand that two different peptidomimetic macrocycles may be co-administered to a subject, or that a peptidomimetic macrocycle and an agent, such as one of the agents set out above, may be co-administered to a subject.

[0068] As used herein, "combination therapy" refers to the treatment of a human or animal individual, comprising administering a first therapeutic agent and a second therapeutic agent to the individual, either sequentially or simultaneously.Generally, the first and second therapeutic agents are administered to the individual separately, not as a mixture.However, there may be embodiments in which the first and second therapeutic agents are mixed before administration.

[0069] "Conservative substitution" as used herein refers to the replacement of an amino acid with another amino acid having similar characteristics (e.g., charge, side chain size, hydrophobicity / hydrophilicity, backbone conformation and rigidity, etc.), which allows frequent changes to be made without changing the biological activity of a protein. Those skilled in the art generally recognize that single amino acid substitutions in non-essential regions of a polypeptide do not substantially change biological activity (see, for example, Watson et al. Molecular Biology of the Gene, The Benjamin / Cummings Pub.Co., p.224 (4th ed.) (1987)). Moreover, substitution of structurally or functionally similar amino acids is unlikely to destroy biological activity. Exemplary conservative substitutions are shown in Table 2. [Table 2] "Dose," "dosage," "unit dose," "unit dosage," "effective amount," and related terms refer to a physically discrete unit containing a predetermined quantity of active ingredient (e.g., peptidomimetic macrocycle) calculated to produce a desired therapeutic effect (e.g., cancer cell death). These terms are synonymous with a therapeutically effective amount, and an amount sufficient to achieve the stated objectives of the methods disclosed herein.

[0070] "Helical stability" refers to the maintenance of α-helical structure by the staples or stitches of the peptidomimetic macrocycle as measured by circular dichroism or NMR. For example, in some embodiments, the peptidomimetic macrocycles disclosed herein exhibit at least a 1.25-fold, 1.5-fold, 1.75-fold, or 2-fold increase in α-helicity as compared to the corresponding unbridged macrocycle as measured by circular dichroism.

[0071] "Macrocycle" refers to a molecule having a chemical structure that includes a ring or rings formed by at least nine covalently bonded atoms.

[0072] As used herein, "macrocyclization reagent" or "macrocycle-forming reagent" refers to any reagent that can be used to prepare the peptidomimetic macrocycles of the invention by mediating a reaction between two reactive groups. The reactive groups can be, for example, azides and alkynes, where macrocyclization reagents include, but are not limited to, Cu reagents, e.g., reagents that provide reactive Cu(I) species, such as CuBr, CuI, or CuOTf, as well as Cu(II) salts, e.g., Cu(CO), that can be converted in situ to active Cu(I) reagents by the addition of a reducing agent, such as ascorbic acid or sodium ascorbate. 2 CH 3 ) 2 , CuSO 4 and CuCl 2 Examples include:

[0073] The macrocyclization reagent is, for example, Cp*RuCl((PPh 3 ) 2 , [Cp*RuCl] 4 The macrocyclization reagent may further include Ru reagents known in the art, such as, for example, Ru(II) or other Ru reagents capable of providing reactive Ru(II) species. In other cases, the reactive group is a terminal olefin. In such embodiments, the macrocyclization reagent or macrocycle-forming reagent is a metathesis catalyst, including, but not limited to, stabilized late transition metal carbene complex catalysts, such as Group VIII transition metal carbene catalysts. For example, such catalysts are Ru and Os metal centers with a +2 oxidation state, 16 electron count, and pentacoordination. Additional catalysts are disclosed in Grubbs et al., "Ring Closing Metathesis and Related Processes in Organic Synthesis," Acc. Chem. Res. 1995, 28, 446-452, and U.S. Pat. No. 5,811,515. In still other cases, the reactive group is a thiol group. In such embodiments, the macrocyclization reagent is a linker functionalized with two thiol-reactive groups, such as, for example, halogen groups.

[0074] "MDM2" refers to mouse double minute 2 protein, also known as E3 ubiquitin-protein ligase. MDM2 is a protein encoded by MDM2 gene in humans. MDM2 protein is a key negative regulator of p53 tumor suppressor. MDM2 protein functions as E3 ubiquitin ligase that recognizes N-terminal transactivation domain (TAD) of p53 tumor suppressor, and also as an inhibitor of p53 transcriptional activation. As used herein, the term MDM2 refers to human homologue. See GenBank Accession No. 228952; GI:228952.

[0075] "MDMX" or "MDM4" refers to mouse double minute X or 4, a protein that shows significant structural similarity to MDM2. MDMX or MDM4 interacts with p53 through a binding domain located in the N-terminal region of the MDMX or MDM4 protein. As used herein, the terms MDMX or MDM4 refer to the same human homologue. See GenBank Accession No. 88702791; GI:88702791.

[0076] "Members," as used herein in conjunction with a macrocycle or macrocycle-forming linker, refer to atoms that form or are capable of forming a macrocycle, and exclude substituent or side chain atoms. By analogy, cyclodecane, 1,2-difluoro-decane, and 1,3-dimethylcyclodecane are all considered 10-membered macrocycles because no hydrogen or fluoro substituents or methyl side chains participate in the formation of the macrocycle.

[0077] "Natural amino acid" refers to any one of the 20 amino acids commonly found in naturally synthesized peptides and known by the one-letter abbreviations A, R, N, C, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y and V.

[0078] A "non-essential" amino acid residue is one that can be altered from the wild-type sequence of a polypeptide without eliminating or substantially altering an essential biological or biochemical activity of the polypeptide (e.g., receptor binding or activation). An "essential" amino acid residue is one that, when altered from the wild-type sequence of the polypeptide, results in eliminating or substantially eliminating an essential biological or biochemical activity of the polypeptide.

[0079] A "peptidomimetic macrocycle" or "bridged polypeptide" refers to a compound that includes multiple amino acid residues linked by multiple peptide bonds and at least one macrocycle-forming linker that forms a macrocycle between a first naturally occurring or non-natural amino acid residue (or analogue) and a second naturally occurring or non-natural amino acid residue (or analogue) in the same molecule. Peptidomimetic macrocycles include embodiments in which the macrocycle-forming linker connects the α-carbon of the first amino acid residue (or analogue) to the α-carbon of the second amino acid residue (or analogue). Peptidomimetic macrocycles may include one or more non-peptide bonds between one or more amino acid residues and / or amino acid analogue residues and may include one or more non-natural amino acid residues or amino acid analogue residues in addition to anything that forms the macrocycle. A "corresponding non-bridged polypeptide", when referred to in the context of a peptidomimetic macrocycle, is understood to refer to a polypeptide of the same amino acid sequence as the peptidomimetic macrocycle, except for the amino acids involved in the bridge of the staples or stitches.

[0080] Unless otherwise indicated, peptidomimetic macrocycles and structures referred to herein are also meant to include peptidomimetic macrocycles that differ only in the presence of one or more isotopically enriched atoms. For example, a hydrogen is replaced by deuterium or tritium, or a carbon atom is replaced by 13 C or 14Peptidomimetic macrocycles having the structures of the invention in which carbon atoms are replaced with C-enriched carbons or in which carbon atoms are replaced with silicon are within the scope of the present disclosure. The peptidomimetic macrocycles disclosed herein may also contain unnatural proportions of atomic isotopes at one or more of the atoms that make up such peptidomimetic macrocycles. For example, peptidomimetic macrocycles may contain, for example, tritium ( 3 H), iodine-125( 125 I) or carbon-14( 14 C). All isotopic variants of the peptidomimetic macrocycles of the invention, whether radioactive or not, are encompassed within the scope of the present disclosure.

[0081] "Pharmaceutically acceptable derivative" refers to any pharma- ceutically acceptable salt, ester, salt of an ester, prodrug or other derivative of the peptidomimetic macrocycle disclosed herein, which upon administration to an individual can provide (directly or indirectly) the peptidomimetic macrocycle disclosed herein. Particularly preferred pharma- ceutically acceptable derivatives are those which, when administered to an individual, enhance the bioavailability of the peptidomimetic macrocycle disclosed herein (e.g., by increasing absorption of an orally administered peptidomimetic macrocycle disclosed herein into the blood) or increase delivery of the active compound to a biological compartment (e.g., the brain or lymphatic system) compared to the parent species. Some pharma- ceutically acceptable derivatives contain chemical groups that increase water solubility or active transport across the gastrointestinal mucosa.

[0082] A "polypeptide" encompasses two or more natural or unnatural amino acids linked by a covalent bond (e.g., an amide bond). The polypeptides described herein include full-length proteins (e.g., fully processed proteins) as well as shorter amino acid sequences (e.g., fragments of natural proteins or synthetic polypeptide fragments).

[0083] "Stability" refers to the maintenance of a defined secondary structure in solution by the peptidomimetic macrocycles of the invention, or resistance to proteolysis in vitro or in vivo, as measured by circular dichroism, NMR or another biophysical measurement. Non-limiting examples of secondary structures contemplated in the present invention are α-helices, β-turns, and β-pleated sheets.

[0084] As used herein, "therapeutically effective amount" or "therapeutically effective dose" refers to the amount of a particular substance sufficient to achieve a desired effect in a treated subject.For example, this may be the amount of the peptidomimetic macrocycle of the present invention required to activate p53 by inhibiting its binding to MDM2 and MDMX.It may also refer to the amount or dose of chemotherapeutic agent or radiation administered to a subject with cancer, which is generally administered to the subject to treat cancer.

[0085] As used herein, "treat" or "treating" refers to administering, internally or externally, a composition containing a therapeutic agent, e.g., any of the peptidomimetic macrocycles of the invention, to a subject or patient having or suspected of having one or more disease symptoms for which the agent has therapeutic or prophylactic activity. Typically, the agent is administered in an amount effective to alleviate one or more disease symptoms in the treated subject or population by inducing regression of such symptoms to any clinically measurable extent or by inhibiting the progression of such symptoms. The amount of a therapeutic agent effective to alleviate any particular disease symptom may vary depending on factors such as the disease state, age, and weight of the patient, as well as the ability of the drug to elicit a desired response in the subject. Whether a disease symptom has been alleviated can be assessed by any clinical measurement normally used by a physician or other skilled health care provider to assess the severity or progression of the symptom. The term further includes postponing the onset of symptoms associated with the disorder and / or reducing the severity of the symptoms of such disorder. The term further includes ameliorating existing uncontrolled or undesirable symptoms, preventing further symptoms, and ameliorating or preventing the underlying cause of such symptoms. Thus, these terms mean that a beneficial result is conferred on a human or animal subject having a disorder, disease or condition or having a potential for developing such a disorder, disease or condition.

[0086] As used herein, "treatment" as applied to a human or veterinary individual refers to therapeutic treatment and encompasses contacting a human or animal individual in need of treatment with a peptidomimetic macrocycle of the invention.

[0087] P53-activating peptidomimetic macrocycles The bridged peptidomimetic macrocycles of the invention have improved properties compared to known peptidomimetic macrocycles, such as those disclosed in WO2020112868. The peptidomimetic macrocycles of the invention also have improved properties over the macrocycles disclosed in more detail in the following references: A. Burgess, KM Chia, S. Haupt, D. Thomas, Y. Haupt and E. Lim. Clinical overview of MDM2 / X targeted therapies. Front. Oncol., 2016, 6, 1-7; K. Kojima, J. Ishizawa and M. Andreeff. Pharmacological activation of wild-type p53 in the therapy of leukemia. Exp. Hematol., 2016, 44, 791-798; V. Tisato, R. Voltan, A. Gonelli, P. Secchiero and G. Zauli. MDM2 / X inhibitors under clinical evaluation: Perspectives for the management of hematological malignancies and pediatric cancer. J. Hematol. Oncol., 2017, 10, 133. In one embodiment, the macrocycles of the invention have superior binding capacity, hi another embodiment, the macrocycles of the invention have improved physicochemical properties.

[0088] The bridged peptidomimetic macrocycles of the invention can have additional MDM2 and / or MDMX (4) attached at the C-terminal tail. In particular, modification of positions 14 and 17 with lipophilic amino acid residues, mostly associated with the helical C-terminal tail, can further increase affinity and / or cellular activity. For example, substitution of alanine with phenylalanine at positions 14 and 17 of macrocycle 3 (SEQ ID NO:3) results in macrocycle 4 (SEQ ID NO:4). This substitution further improves cellular activity at 0% serum compared to macrocycle 3. Macrocycle 4 shows a similar overall helical propensity in circular dichroism (CD) compared to macrocycle 3.

[0089] In one embodiment, substitution of alanine at position 14 of macrocycle 3 with glutamic acid results in macrocycle 11 (SEQ ID NO:11), which exhibits improved cellular activity over macrocycle 3. This improvement is believed to be due to an interaction with MDM2 arginine 97.

[0090] Additional linkages at the tail can be engineered with the right set of physicochemical properties in the molecule to improve stability, solubility, and / or cellular activity. In one embodiment, the introduction of negatively charged alpha amino acid residues at positions 12 and 16 can improve the amphipathic and overall properties of the peptide. For example, replacement of the alanine at position 16 of macrocycle 4 (SEQ ID NO: 4) with alpha-methylglutamic acid results in macrocycle 9 (SEQ ID NO: 9), which has further improved cellular activity in 10% serum compared to macrocycle 4. Macrocycle 9 also exhibits better solubility of 153 uM compared to close analogs of macrocycles 5 and 7.

[0091] Combining phenylalanines at positions 14 and 17 with glutamic acid at position 12 in macrocycle 12 (SEQ ID NO:12) gives macrocycle 13 (SEQ ID NO:13), which exhibits further improved binding and cellular activity (in both 0% and 10% serum) compared to macrocycle 12 and macrocycle 2. Additionally, macrocycle 13 exhibits improved solubility of 167 uM and superior overall helical propensity in CD.

[0092] Engineering the right set of binding characteristics and physicochemical properties can yield "cleaner" drugs, such as compounds with improved potency and selectivity. Macrocycle 9, which features an improved amphipathic profile compared to macrocycle 4, exhibits a selectivity profile in counterscreening assays.

[0093] Macrocycle 11, which features improved amphipathicity and cellular activity compared to macrocycle 3, also shows at least a two-fold improvement in a p53-dependent HTC116 cell proliferation assay and a cleaner profile in a p53-nul Ca Ski counterscreening proliferation assay.

[0094] Furthermore, macrocycle 13 exhibits an improved cellular activity profile in 10% serum, resulting in a greater than 7-fold improvement in the HTC116 cell proliferation assay compared to macrocycle 2.

[0095] Additional modifications in the staple can further improve the overall properties, for example, the use of a dialkyne staple in macrocycle 13 provides an additional advantage in improving the potency of cell proliferation assays.

[0096] Here, X 1 and X 2 Only the staple between is listed, but LTFX 1 - E (SEQ ID NO: 23) linking L and E, or Z 1 -Z 2 -Z 3 -Z 4 -Z 5 Z in 1 and Z 5 Additional staples linking (as lactam or carbon-based i, e.g., i+staple) are also contemplated.

[0097] Thus, the alternative tails disclosed herein provide improved binding and physicochemical properties. Unexpected properties are also obtained with alkyne staples that result in clean peptides due to their on-target vs. off-target profile. Combinations of staple types, staple positions and C-terminal modifications can result in unexpected biological specificity and activity. Overall, the peptidomimetic macrocycles disclosed herein provide improved biological profiles.

[0098] Pharmaceutical Compositions Also disclosed herein are pharmaceutical compositions comprising the peptidomimetic macrocycles of the present disclosure. The peptidomimetic macrocycles can be used in combination with any suitable pharmaceutical carrier or excipient. Such pharmaceutical compositions comprise a therapeutically effective amount of one or more peptidomimetic macrocycles and a pharma-ceutically acceptable excipient(s) and / or carrier(s). The particular formulation will be suitable for the mode of administration. In certain embodiments, the pharma-ceutically acceptable carrier can be water or a buffer.

[0099] Excipients included in pharmaceutical compositions have different purposes, for example, depending on the nature of the drug and the mode of administration. Examples of commonly used excipients include, but are not limited to, saline, buffered saline, dextrose, water-for-infection, glycerol, ethanol and combinations thereof, stabilizers, solubilizers and surfactants, buffers and preservatives, isotonicity agents, bulking agents, lubricants (talc or silica, and fats such as vegetable stearin, magnesium stearate or stearic acid), emulsifiers, suspending agents or viscosity agents, inert diluents, fillers (cellulose, dibasic calcium phosphate, vegetable fats and oils, lactose, sucrose, glucose, mannitol, sorbitol, calcium carbonate, and magnesium stearate), disintegrants (crosslinked polyvinylpyrrolidone, sodium starch glycolate, crosslinked sodium carboxymethylcellulose, etc.), binders (starch, Examples of suitable preservatives include, but are not limited to, cellulose, gelatin, cellulose, methylcellulose, or modified celluloses such as microcrystalline cellulose, hydroxypropyl cellulose, sugars such as sucrose and lactose, or sugar alcohols such as xylitol, sorbitol or maltitol, polyvinylpyrrolidone and polyethylene glycols), humectants, antimicrobial agents, chelating agents, coatings (such as cellulose film coatings, synthetic polymers, shellac, corn protein zein or other polysaccharides, and gelatin), preservatives (including vitamin A, vitamin E, vitamin C, retinyl palmitate and selenium, cysteine, methionine, citric acid and sodium citrate, and synthetic preservatives including methylparaben and propylparaben), sweeteners, fragrances, flavorings, coloring agents, administration aids, and combinations thereof.

[0100] Carriers are compounds and substances that improve and / or extend the delivery of active ingredients to a subject in the context of a pharmaceutical composition. Carriers can help to extend the in vivo activity of a drug in a subject or delay the release of a drug using controlled release technology. Carriers can also reduce drug metabolism and / or reduce the toxicity of a drug in a subject. Carriers can also be used to target the delivery of a drug to specific cells or tissues in a subject. Common carriers (both hydrophilic and hydrophobic carriers) include fat emulsions, lipids, PEGylated phospholipids, PEGylated liposomes, PEGylated liposomes coated with cyclic RGD peptide c (RGDDYK (SEQ ID NO: 24)) via a PEG spacer, liposomes and lipospheres, microspheres (including those made of biodegradable polymers or albumin), polymer matrices, biocompatible polymers, protein-DNA complexes, protein conjugates, red blood cells, vesicles, nanoparticles, and side chains for carbohydrate staples. The aforementioned carriers can also be used to enhance the cell membrane permeability of the peptidomimetic macrocycles of the invention.

[0101] Pharmaceutical compositions adapted for oral administration may be provided as discrete units such as capsules or tablets; as powders or granules; as solutions, syrups or suspensions (in aqueous or non-aqueous liquids; or as edible foams or whips; or as emulsions). Suitable excipients for tablets or hard gelatin capsules include lactose, corn starch or derivatives thereof, stearic acid or salts thereof. Suitable excipients for use with soft gelatin capsules include, for example, vegetable oils, waxes, fats, semi-solid or liquid polyols, and the like. For the preparation of solutions and syrups, excipients that can be used include, for example, water, polyols and sugars. For the preparation of suspensions, oils, for example vegetable oils, can be used to provide oil-in-water or oil-in-water suspensions. In certain circumstances, delayed release preparations can be advantageous, and compositions that can deliver peptidomimetic macrocycles in a delayed or controlled release manner can also be prepared. Prolonged gastric retention poses the problem of degradation by enzymes present in the stomach, therefore enteric coated capsules can also be prepared by standard techniques in the art in which the active substance for release is lowered in the gastrointestinal tract.

[0102] Pharmaceutical compositions adapted for transdermal administration may be presented as discrete patches intended to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. For example, the active ingredient may be delivered from the patch by iontophoresis, as generally described in Pharmaceutical Research, 3(6):318 (1986).

[0103] Pharmaceutical compositions adapted for topical administration can be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.When formulated in ointments, the active ingredient can be used with either a paraffinic ointment base or a water-miscible ointment base.Alternatively, the active ingredient can be formulated in a cream with an oil-in-water cream base or a water-in-oil base.Pharmaceutical compositions adapted for topical administration to the eye include eye drops, in which the active ingredient is dissolved or suspended in a suitable carrier, particularly an aqueous solvent.Pharmaceutical compositions adapted for topical administration in the mouth include lozenges, troches and mouthwashes.

[0104] Pharmaceutical compositions adapted for rectal administration may be presented as suppositories or enemas.

[0105] Pharmaceutical compositions adapted for nasal administration wherein the carrier is a solid include a coarse powder having a particle size, for example in the range 20 to 500 microns, administered in the manner in which snuff is taken, i.e. by rapid inhalation through the nasal passages from a container of the powder held close to the nose. Compositions wherein the carrier is a liquid and suitable for administration as a nasal spray or as nasal drops include aqueous or oil solutions of the active ingredient.

[0106] Pharmaceutical compositions adapted for administration by inhalation include fine particle dusts or mists, which may be generated by means of various types of metered dose pressurized aerosols, nebulizers or insufflators.

[0107] Pharmaceutical compositions adapted for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations.

[0108] Pharmaceutical compositions adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions that may contain antioxidants, buffers, bacteriostats and solutes that render the formulation substantially isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions that may contain suspending agents and thickening agents. Excipients that may be used for injection solutions include, for example, water for injection, alcohols, polyols, glycerin and vegetable oils. The compositions may be provided in unit-dose or multi-dose containers, such as sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) state requiring only the addition of a sterile liquid carrier, such as water or saline, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets. Pharmaceutical compositions may contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, odorants, salts (the substance of the present invention itself may be provided in the form of a pharma-ceutically acceptable salt), buffers, coating agents or antioxidants. They may also contain therapeutically active agents in addition to the substance of the present invention.

[0109] The pharmaceutical composition may be administered in any convenient manner, such as by topical, intravenous, intraperitoneal, intramuscular, intratumoral, subcutaneous, intranasal or intradermal routes. The pharmaceutical composition is administered in an amount effective for the treatment and / or prevention of a particular indication. In general, the pharmaceutical composition is administered in an amount of at least about 0.1 mg / kg to about 100 mg / kg of body weight. In most cases, the dosage is about 10 mg / kg to about 1 mg / kg of body weight daily, taking into account the route of administration, symptoms, etc.

[0110] Dosages of the peptidomimetic macrocycles of the present disclosure can vary within a wide range, depending on the location, origin, identity, extent and severity of the cancer, the age and condition of the individual being treated, etc. Ultimately, the physician will determine the appropriate dosage to be used.

[0111] The peptidomimetic macrocycles may also be used in accordance with the present disclosure by expression of the antagonist in vivo, i.e., by gene therapy. Use of a peptide or composition in a gene therapy setting is also considered a type of "administration" of the peptide for purposes of the present invention.

[0112] Thus, the present invention also relates to a method of treating a subject having cancer, comprising administering to a subject in need of treatment a pharmaceutical composition comprising a pharma- ceutical effective amount of one or more peptidomimetic macrocycles of the present invention, or one or more antagonists. The term "cancer" is intended to be broadly interpreted and encompasses all conditions of abnormal cell proliferation and / or cell division. Examples include: carcinomas, including but not limited to adenocarcinoma, squamous cell carcinoma, adenosquamous cell carcinoma, undifferentiated carcinoma, large cell carcinoma, small cell carcinoma, and cancers of the skin, breast, prostate, bladder, vagina, cervix, uterus, liver, kidney, pancreas, spleen, lung, trachea, bronchus, colon, small intestine, stomach, esophagus, gallbladder; sarcomas, including but not limited to chondrosarcoma, Ewing's sarcoma, malignant hemangioendothelioma, malignant Schwannoma, osteosarcoma, soft tissue sarcoma, and cancers of bone, cartilage, fat, muscle, blood vessels, and hematopoietic tissue; lymphomas and leukemias, including but not limited to mature B-cell tumors, e.g., chronic myeloid leukemia, chronic myeloid leukemia, chronic myeloma, and chronic myeloma. Lymphocytic leukemia / small lymphocytic lymphoma, B-cell prolymphocytic leukemia, lymphoma and plasma cell neoplasms, mature T-cell and natural killer (NK) cell neoplasms, such as T-cell prolymphocytic leukemia, T-cell large granular lymphocytic leukemia, aggressive NK cell leukemia and adult T-cell leukemia / lymphoma, Hodgkin's lymphoma, and immunodeficiency-associated lymphoproliferative disorders; germ cell tumors, including but not limited to testicular and ovarian cancer; blastomas, including but not limited to hepatoblastoma, medulloblastoma, nephroblastoma, neuroblastoma, pancreatic blastoma, pleuropulmonary blastoma and retinoblastoma. This term also encompasses benign tumors.

[0113] In each embodiment, the individual or subject to be treated is a human or a non-human animal, such as a non-human primate, a bird, a horse, a cow, a goat, a sheep, a companion animal such as a dog, a cat or a rodent, or another mammal. In some embodiments, the subject is a human.

[0114] Kits are also provided that include one or more containers filled with one or more components of the pharmaceutical composition of the present disclosure, such as a pharmaceutical composition comprising a peptidomimetic macrocycle of the present disclosure and a pharma- ceutically acceptable carrier or diluent. Such container(s) may be associated with a notice in the form prescribed by a government agency regulating the manufacture, use or sale of pharmaceutical or biological products, which notice reflects the agency's approval of the manufacture, use or sale for human administration. Additionally, the pharmaceutical composition may be used in combination with other therapeutic compounds.

[0115] Combination therapy including chemotherapy The peptidomimetic macrocycles disclosed herein may be administered to individuals with cancer in combination with chemotherapy. The individual may receive chemotherapy simultaneously with administration of the peptidomimetic macrocycle to the individual. The individual may receive chemotherapy after the individual has completed a course of treatment with the peptidomimetic macrocycle. The individual may be administered the peptidomimetic macrocycle after the individual has completed a course of treatment with a chemotherapeutic agent. The combination therapy of the invention may also be administered to individuals with recurrent or metastatic cancer with disease progression or recurrent cancer who are undergoing or have completed chemotherapy.

[0116] The chemotherapy may include a chemotherapeutic agent selected from the group consisting of: (i) Alkylating agents, including but not limited to bifunctional alkylating agents, cyclophosphamide, mechlorethamine, chlorambucil, and melphalan; (ii) monofunctional alkylating agents, including but not limited to dacarbazine, nitrosoureas, and temozolomide (oral dacarbazine); (iii) Anthracyclines, including, but not limited to, daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone and valrubicin; (iv) cytoskeletal disrupting agents (taxanes), including but not limited to, paclitaxel, docetaxel, abraxane, and taxotere; (v) Epothilones, including but not limited to ixabepilone and utiderone; (vi) histone deacetylase inhibitors, including but not limited to, vorinostat and romidepsin; (vii) inhibitors of topoisomerase I, including but not limited to, irinotecan and topotecan; (viii) inhibitors of topoisomerase II, including but not limited to, etoposide, teniposide and tafluposide; (ix) Kinase inhibitors, including but not limited to, bortezomib, erlotinib, gefitinib, imatinib, vemurafenib, and vismodegib; (x) Nucleotide analogs and precursor analogs, including, but not limited to, azacitidine, azathioprine, fluoropyrimidines (such as capecitabine, carmoful, doxifluridine, fluorouracil, and tegafur), cytarabine, gemcitabine, hydroxyurea, mercaptopurine, methotrexate, and thioguanine (formerly thioguanine); (xi) peptide antibiotics, including but not limited to, bleomycin and actinomycin; platinum-based drugs, including but not limited to, carboplatin, cisplatin, and oxaliplatin; (xii) retinoids, including but not limited to tretinoin, alitretinoin, and bexarotene; and (xiii) Vinca alkaloids and derivatives, including, but not limited to, vinblastine, vincristine, vindesine, and vinorelbine.

[0117] The choice of the dose of the chemotherapeutic agent for chemotherapy depends on several factors, including the serum or tissue turnover rate of the entity, the level of symptoms, the immunogenicity of the entity, and the accessibility of the target cells, tissues or organs in the individual being treated. The dose of the additional therapeutic agent must be an amount that produces an acceptable level of side effects. Thus, the dose and frequency of administration of each additional therapeutic agent depends in part on the specific therapeutic agent, the severity of the cancer being treated, and the characteristics of the patient. Guidance is available for selecting the appropriate dose of antibodies, cytokines, and small molecules. For example, Wawrzynczak (1996) Antibody Therapy, Bios Scientific Pub. Ltd, Oxfordshire, UK; Kresina (ed.) (1991) Monoclonal Antibodies, Cytokines and Arthritis, Marcel Dekker, New York, NY; Bach (ed.) (1993) Monoclonal Antibodies and Peptide Therapy in Autoimmune Diseases, Marcel Dekker,New York,NY;Baert et al.(2003)New Engl.J.Med.348:601-608;Milgrom et al.(1999)New Engl.J.Med.341:1966-1973;Slamon et al.(2001)New Engl.J.Med.344:783-792;Beniaminovitz et al. al.(2000)New Engl.J.Med.342:613-619;Ghosh et al.(2003)New Engl.J.Med.348:24-32;Lipsky et al.(2000)New Engl.J.Med.343:1594-1602;Physicians' Desk Reference 2003(Physicians' Desk Reference,57th Ed);Medical Economics Company;ISBN:1563634457;57th edition (November 2002).Determination of an appropriate dosing regimen may be made by the clinician using, for example, parameters or factors known or suspected in the art to affect treatment or predicted to affect treatment, and depends, for example, on the individual's medical history (e.g., previous therapies), the type and stage of the cancer being treated and biomarkers of response to one or more of the therapeutic agents in the combination therapy.

[0118] The embodiment of the combination therapy is contemplated, which includes a chemotherapy step comprising either platinum-containing chemotherapy, pemetrexed and platinum chemotherapy or carboplatin, and paclitaxel or nab-paclitaxel. In certain embodiments, the combination therapy with the chemotherapy step can be used to treat at least NSCLC and HNSCC.

[0119] Combination therapy can be used to treat any proliferative disease, particularly cancer.In certain embodiments, combination therapy can be used to treat melanoma, non-small cell lung cancer, head and neck cancer, urothelial carcinoma, breast cancer, gastrointestinal cancer, multiple myeloma, hepatocellular carcinoma, non-Hodgkin's lymphoma, renal carcinoma, Hodgkin's lymphoma, mesothelioma, ovarian cancer, small cell lung cancer, esophageal cancer, anal cancer, biliary tract cancer, colorectal cancer, cervical cancer, thyroid cancer, or salivary gland cancer.

[0120] In another embodiment, the combination therapy may be used to treat pancreatic cancer, bronchial cancer, prostate cancer, pancreatic cancer, gastric cancer, ovarian cancer, bladder cancer, brain or central nervous system cancer, peripheral nervous system cancer, uterine or endometrial cancer, oral or pharyngeal cancer, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, small intestine or appendix cancer, adrenal cancer, osteosarcoma, chondrosarcoma, or cancer of the blood tissue.

[0121] In certain embodiments, the combination therapy may be used to treat one or more cancers selected from melanoma (metastatic or unresectable), primary mediastinal large B-cell lymphoma (PMBCL), urothelial carcinoma, MSIHC, gastric cancer, cervical cancer, hepatocellular carcinoma (HCC), Merkel cell carcinoma (MCC), renal cell carcinoma (including advanced cancer), and cutaneous squamous cell carcinoma.

[0122] Additional combination therapy The peptidomimetic macrocycles disclosed herein may be used in combination with other therapies. For example, combination therapy may include compositions comprising peptidomimetic macrocycles formulated with and / or co-administered with one or more additional therapeutic agents, such as hormonal therapy, vaccines, and / or other immunotherapy. In other embodiments, the peptidomimetic macrocycles are administered in combination with other therapeutic treatment modalities, including surgery, radiation, cryosurgery, and / or hyperthermia. Such combination therapy may advantageously utilize lower amounts of administered therapeutic agents, thus avoiding possible toxicity or complications associated with various monotherapies.

[0123] By "in combination with," it is not intended to imply that the therapies or therapeutic agents must be administered simultaneously and / or formulated together for delivery, even though these delivery methods are within the scope described herein. The peptidomimetic macrocycle may be administered simultaneously with, prior to, or after one or more other additional therapies or therapeutic agents. The peptidomimetic macrocycle and other agents or treatment protocols may be administered in any order. In general, the agents are administered at a dose and / or time schedule determined for that agent. It will be further understood that the additional therapeutic agents utilized in the combination may be administered together in a single composition or may be administered separately in different compositions. In general, it is expected that the additional therapeutic agents utilized in combination will be utilized at levels that do not exceed the levels at which they are utilized individually. In some embodiments, the levels utilized in combination will be lower than the levels utilized individually.

[0124] In certain embodiments, the peptidomimetic macrocycles described herein are administered in combination with one or more checkpoint inhibitors or antagonists of programmed death receptor 1 (PD-1) or its ligands PD-L1 and / or PD-L2. The inhibitors or antagonists can be antibodies, antigen-binding fragments, immunoadhesins, fusion proteins, or oligopeptides. In some embodiments, the anti-PD-1 antibody is selected from nivolumab (OPDIVO, Bristol Myers Squibb, New York, New York), pembrolizumab (KEYTRUDA, Merck Sharp&Dohme Corp, Kenilworth, NJ USA), setiplimab (Regeneron, Tarrytown, NY) or pidilizumab (CT-011). In some embodiments, the PD-1 inhibitor is an immunoadhesin (e.g., an immunoadhesin that includes an extracellular or PD-1 binding portion of PD-L1 or PD-L2 fused to a constant region (e.g., an Fc region of an immunoglobulin sequence). In some embodiments, the PD-1 inhibitor is AMP-224. In some embodiments, the PD-L1 inhibitor is an anti-PD-L1 antibody, such as durvalumab (IMFINZI, AstraZeneca, Wilmington, DE), atezolizumab (TECENTRIQ, Roche, Zurich, CH), or avelumab (BAVENCIO, EMD Serono, Billerica, MA). In some embodiments, the anti-PD-L1 binding antagonist is selected from YW243.55.S70, MPDL3280A, MEDI-4736, MSB-0010718C, or MDX-1105.

[0125] The following examples are intended to facilitate a further understanding of the invention.

[0126] Common methods The available crystal structure of ATSP-7041 co-crystallized with MDM4 was used to model the stapled peptides with C-terminal extensions. All these models were subjected to MD (molecular dynamics) simulations for further refinement. MD simulations were performed for the free peptides and peptide-MDM2 complexes. The Xleap module of AMBER16 was used to prepare the systems for MD simulations. Hydrogen atoms were added and the N-terminus, C-terminus of the peptides were blocked with residues ACE (acetyl) and NHE (primary amide). The parameters for the stapled linker were taken from a previous study (Tan, YSet al. Benzene Probes in Molecular Dynamics Simulations Reveal Novel Binding Sites for Ligand Design. J Phys Chem Lett 7,3452-3457). All the simulation systems were neutralized with an appropriate number of counterions. The neutralized systems were solvated in an octahedral box containing TIP3P water molecules, leaving at least 10 Å between the solute atoms and the boundaries of the box. MD simulations were performed using the AMBER 16 package coupled with the ff14SB force field. All MD simulations were performed in explicit solvent at 300 K. During all simulations, long-range electrostatic interactions were treated with the particle mesh Ewald method using a real-space cutoff distance of 9 Å. Bond vibrations involving hydrogen atoms were suppressed using the settle algorithm, allowing a time step of 2 fs during the simulations.

[0127] The solvent molecules and counterions were first relaxed using energy minimization with restraints on the protein and peptide atoms. This was followed by uncontrolled energy minimization to remove any steric clashes. MD simulations with positional restraints on the protein and peptide over a period of 0.25 ns (force constant: 50 kcal mol -1 Å -2) to gradually heat the system from 0 to 300°K, allowing the water molecules and ions to move freely, followed by gradually removing the positional constraints and a 2 ns unconstrained equilibration at 300°K. The resulting system was used as the starting structure for each generation step of the MD simulations. For each case, three independent MD simulations (using different initial random velocities) were performed starting from the well-equilibrated structure. Each MD simulation was carried out for 250 ns and the conformations were recorded every 4 ps.

[0128] To improve the sampling of higher-order structures, each of these peptides was subjected to biasing potential replica exchange molecular dynamics (BP-REMD) simulations. The BP-REMD technique is a variant of the Hamiltonian-REMD method that includes a biasing potential to promote dihedral angle transitions along the replica (Kannan S, Zacharias M (2007) Enhanced sampling of peptide and protein conformations using replica exchange simulations with a peptide backbone biasing-potential. Proteins. 66: 697-706; Ostermeir K, Zacharias M. Hamiltonian replica-exchange simulations with adaptive biasing of peptide backbone and side chain dihedral angles. J. Comput. Chem., 35 (2014)). For each system, BP-REMD was performed on eight replicas, including an unbiased reference replica. BP-REMD was performed for 50 ns, and exchanges between adjacent replicas were attempted every 2 ps and accepted or rejected according to the Metropolis criteria. The conformations sampled with the reference replica (unbiased) were used for further analysis. Simulation trajectories were visualized using VMD, and figures were generated using Pymol.

[0129] Binding energy calculations and energy decomposition analysis: The molecular mechanism Poisson-Boltzmann surface area (MMPBSA) method was used to calculate the binding free energy between the peptides and their partner proteins, and 250 conformations extracted from the last 50 ns of the simulation were used to calculate the binding energy. The entropy calculations are computationally intensive and do not easily converge, and are therefore ignored. The MMGBSA energy decomposition scheme was used to decompose the effective binding energy into the contributions of individual residues. MMGBSA calculations were performed in the same way as MMPBSA calculations. The polar contributions to the solvation free energy were determined using the mbondi2 radius, applying the generalized born (GB) method (igb = 2). The nonpolar contributions were estimated using the ICOSA method by a solvent accessible surface area (SASA)-dependent term, using a surface tension proportionality constant of 0.0072 kcal / mol Å2. The contribution of the peptide residues was further investigated by performing in silico alanine scanning, in which each of the peptide residues was mutated to D-alanine in each conformation of the MD simulation and the change with respect to the binding energy of the wild-type peptide was calculated using MMPBSA.

[0130] Peptide synthesis Peptides were synthesized using RINK resin and Fmoc-protected amino acids sequentially coupled with diisopropylcarbodiimide / 1-hydroxybenzotriazole (DIC / HOBT) activating agents. Double coupling reactions were performed on the first amino acid and also at the staple positions. At these latter positions, the activating reagent was switched to N,N-diisopropylethylamine / hexafluorophosphate azabenzotriazole tetramethyluronium (DIEA / HATU) for better coupling efficiency.

[0131] The ring-closing metathesis reaction was carried out by first washing the resin with dichloromethane (DCM) three times, followed by the addition of the first generation Grubbs catalyst (35 mg dissolved in 5 mL of DCM) and reacting for 2 h (all steps using Grubbs catalyst were carried out in the dark). The ring-closing metathesis (RCM) reaction was repeated to ensure complete reaction. After the RCM was completed, a test cleavage was carried out to ensure sufficient yield. The peptide was cleaved and then purified as a mixture of cis-trans isomers by reversed-phase high performance liquid chromatography (RP-HPLC). The resin was first washed with DCM three times, followed by the addition of tetrahydrofuran (THF), diisopropylethylamine (DIPEA), Pd(PPh 3 ) 2 Cl 2 The Glaser alkyne cross-coupling reaction was carried out on the resin by adding CuI followed by sonication and heating for 16 h at 30° C. The mixture was filtered and washed with dimethylformamide (DMF).

[0132] Production of MDM2 protein The human MDM2 1-125 sequence was cloned into the pNIC-GST vector for use in peptide binding assays. The TV cleavage site was changed from ENLYFQS (SEQ ID NO:25) to ENLYFQG (SEQ ID NO:26) resulting in a fusion protein with the following sequence (SEQ ID NO:14): [Sequence table] TIFF2024544620000010.tif47151 The corresponding plasmids were transformed into BL21(DE3) Rosetta T1R E. coli cells and grown under kanamycin selection. Bottles of 750 mL Terrific Broth (TB) and 100 μL antifoam 204 (Sigma-Aldrich) supplemented with the appropriate antibiotics were inoculated with 20 mL seed cultures grown overnight. Cultures were incubated at 37°C in a LEX system (Harbinger Biotech) with aeration and agitation by bubbling filtered air through the culture. When the culture OD600 reached 2, the temperature of the LEX system was reduced to 18°C ​​and the culture was induced with 0.5 mM IPTG after 60 min. Protein expression was allowed to continue overnight. Cells were harvested by centrifugation at 4000g for 10 min at 15°C. The supernatant was discarded and the cell pellet was resuspended in lysis buffer (1.5 mL per gram of cell pellet). The cell suspension was stored at -80°C prior to purification workup.

[0133] The resuspended cell pellet suspension was thawed and sonicated (Sonics Vibra-cell) on ice for 3 min at 70% amplitude, 3 sec on / off. The lysate was clarified by centrifugation at 47000g for 25 min at 4°C. The supernatant was filtered through a 1.2um syringe filter and loaded onto an AKTA Xpress system (GE Healthcare). The purification regime is briefly described below.

[0134] The lysate was loaded onto a 1 mL Ni-NTA Superflow column (Qiagen) equilibrated with 10 column volumes of Wash 1 buffer. Overall buffer conditions were as follows: Immobilized metal affinity chromatography (IMAC) wash 1 buffer: 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 500 mM NaCl, 10 mM imidazole, 10% (v / v) glycerol, 0.5 mM tris(2-carboxyethyl)phosphine (TCEP), pH 7.5; IMAC wash 2 buffer: 20 mM HEPES, 500 mM NaCl, 25 mM imidazole, 10% (v / v) glycerol, 0.5 mM TCEP, pH 7.5; IMAC elution buffer: 20 mM HEPES, 500 mM NaCl, 500 mM imidazole, 10% (v / v) glycerol, 0.5 mM TCEP, pH 7.5.

[0135] The sample was loaded until air was detected by the air sensor at 0.8 mL / min. The column was then washed with 20 column volumes of Wash 1 buffer followed by 20 column volumes of Wash 2 buffer. The protein was eluted with 5 column volumes of Elution Buffer. The eluted protein was collected and stored in a sample loop on the system and then injected onto a gel filtration (GF) column. The elution peak was collected in 2 mL fractions and analyzed on an SDS-PAGE gel. The entire purification was carried out at 4 °C. Relevant peaks were pooled and TCEP was added to a total concentration of 2 mM. The protein sample was concentrated to approximately 15 mg / mL at 15 °C in a Vivaspin 20 filter concentrator (VivaScience) (<18 kDa-5K MWCO, 19-49 kDa-10K MWCO, >50 kDa-30K MWCO). The final protein concentration was assessed by measuring absorbance at 280 nm with a Nanodrop ND-1000 (Nano-Drop Technologies). The final protein purity was assessed on an SDS-PAGE gel. The final protein batch was then aliquoted into smaller fractions, frozen in liquid nitrogen, and stored at -80°C.

[0136] Production of MDM4 protein MDM4 protein was cloned into pNIC-GST vector and expressed with the LEX system (Harbinger Biotech) of Protein Production Platform (PPP) at NTU (Nanyang Technological University) School of Biological Sciences. The glycerol stock was used to start an inoculation culture in 20 mL of Terrific Broth containing 8 g / L glycerol supplemented with kanamycin. The culture was incubated overnight at 37 °C and 200 rpm. The next morning, the seed culture was inoculated into a 750 mL bottle of Terrific Broth containing 8 g / L glycerol supplemented with kanamycin and 100 μL of antifoam 204 (Sigma-Aldrich).

[0137] Cultures were incubated at 37°C in a LEX system with aeration and agitation by bubbling filtered air through the culture. Once the OD600 reached approximately 2, the temperature was reduced to 18°C ​​and the culture was induced with 0.5 mM IPTG after 30-60 min. Protein expression was allowed to continue overnight. The following morning, cells were harvested by centrifugation at 4200 rpm for 10 min at 15°C. The supernatant was discarded and cells were resuspended in lysis buffer (100 mM HEPES, 500 mM NaCl, 10 mM imidazole, 10% glycerol, 0.5 mM TCEP, pH 8.0, and Benzonase (4 uL per 750 mL culture) and 250 U / μL of Merck Protease Inhibitor Cocktail Set III, EDTA free from Calbiochem (diluted 1000-fold in lysis buffer)) at 200 rpm for approximately 30 min at 4°C and stored at -80°C.

[0138] The resuspended cell pellet suspension was thawed and sonicated (Sonics Vibra-cell) on ice for 3 min at 70% amplitude, 3 s on / off. The lysate was clarified by centrifugation at 47000g for 25 min at 4°C. The supernatant was filtered through a 1.2 μm syringe filter and loaded onto an AKTA Xpress system (GE Healthcare) equipped with a 1 mL Ni-NTA Superflow (Qiagen) IMAC column. The column was washed with 20 column volumes (CV) of wash buffer 1 (20 mM HEPES, 500 mM NaCl, 10 mM imidazole, 10% (v / v) glycerol, 0.5 mM TCEP, pH 7.5) and 20 CV of wash buffer 2 (20 mM HEPES, 500 mM NaCl, 25 mM imidazole, 10% (v / v) glycerol, 0.5 mM TCEP, pH 7.5) or until a stable baseline for 3 min and a delta base of 5 mAU (0.8 mL / min) were obtained, respectively.

[0139] MDM4 protein was eluted with elution buffer (20 mM HEPES, 500 mM NaCl, 500 mM imidazole, 10% (v / v) glycerol, 0.5 mM TCEP, pH 7.5) and the elution peak (collection start: >50 mAU, gradient >200 mAU / min, collection stop: <50 mAU, stable plateau 0.5 min, delta plateau 5 mAU) was collected and stored in a sample loop on the system, then injected onto an equilibrated gel filtration (GF) column (HiLoad 16 / 60 Superdex 200 prep grade (GE Healthcare)) and eluted with 20 mM HEPES, 300 mM NaCl, 10% (v / v) glycerol, 0.5 mM TCEP, pH 7.5 at a flow rate of 1.2 mL / min. The elution peak (collection start: >20mAU, gradient >10mAU / min, collection stop: <20mAU, gradient >10mAU / min, minimum peak width 0.5 min) was collected in 2 mL fractions. The entire purification was carried out at 4°C. Relevant peaks were pooled and TCEP was added to a final concentration of 2 mM. Protein samples were concentrated to approximately 15 mg / mL in Vivaspin 20 filter concentrators (VivaScience) at 15°C. Final protein concentration was assessed by measuring absorbance at 280 nm on a Nanodrop ND-1000 (Nano-Drop Technologies). Final protein purity was assessed by SDS-PAGE and purified MDM4 protein was frozen in liquid nitrogen and stored at -80°C.

[0140] Circular dichroism (CD) Prior to the experiment, 5 μl of 10 mM stock peptide was mixed with 45 μl of 100% methanol and dried for 2 h in a SpeedVac concentrator (Thermo Scientific). The dried peptide was reconstituted to a concentration of 1 mM in a buffer containing 1 mM HEPES pH 7.4 and 5% methanol. Peptide samples were placed in quartz cuvettes with a path length of 0.2 cm and CD spectra were recorded from 300 to 190 nm at 25 °C using a Chirascan-plus qCD instrument (Applied Photophysics). The actual concentration of the peptide was determined by the absorbance of the peptide at 280 nM. Estimation of the secondary structure content of the peptides was performed by converting the CD spectra to the average value of residue ellipticities before deconvolution using CDNN software (distributed by Applied Photophysics). All experiments were performed in duplicate.

[0141] Isothermal titration calorimetry (ITC) All experiments were performed in duplicate using a MicroCal PEAQ-ITC Automated system. Peptides at 100-200 μM were titrated into 20 μM purified recombinant human MDM2 protein (amino acids 1-125; SEQ ID NO: 14) over 40 injections of 1 μL each. For highly concentrated and insoluble peptides, reverse ITC was performed by titrating 200 μM MDM2 protein into 20 μM peptide. All proteins and peptides were dialyzed overnight in a buffer containing 1× phosphate-buffered saline (PBS) pH 7.2, 3% DMSO and 0.001% Tween-20. Data analysis was performed using MicroCal PEAQ-ITC analysis software.

[0142] MDM2 binding assay Purified MDM2 (1-125; SEQ ID NO: 14) protein was incubated with 50 nM carboxyfluorescein (FAM)-labeled 12 / 1 peptide (FAM-RFMDYWEGL-NH 2; SEQ ID NO: 15). The dissociation constant for the titration of MDM2 against the FAM-labeled 12 / 1 peptide was determined by fitting the experimental data to the 1:1 binding model equation shown below.

[0143] Formula 1:

number

number

[0144] p53 beta-lactamase reporter gene cellular functional assay HCT116 cells were stably transfected with a p53-responsive β-lactamase reporter and seeded at a density of 8,000 cells / well in 384-well plates. Cells were maintained in McCoy's 5A medium containing 10% fetal bovine serum (staining buffer or FBS), blasticidin and penicillin / streptomycin. Cells were incubated overnight, followed by removal of cell growth medium and replacement with Opti-MEM containing either 0% FBS or 10% FBS. Peptides were then dispensed into each well using a liquid handler, ECHO 555, and incubated for 4 / 16 h. The final working concentration of dimethyl sulfoxide (DMSO) was 0.5%. β-lactamase activity was detected using ToxBLAzer Dual Screen (Invitrogen) according to the manufacturer's instructions. Measurements were performed using an Envision multiplate reader (Perkin-Elmer). Maximal p53 activity was defined as the amount of β-lactamase activity induced by 50 μM azido-ATSP-7041 (stapled p53 peptide; Aileron Therapeutics, Inc.), which was determined by titration against HCT116 cells as the maximum amount of p53 activity induced by azido-ATSP-7041.

[0145] Lactate dehydrogenase release assay (LDH) HCT116 cells were seeded in 384-well plates at a density of 8000 cells / well. Cells were maintained in McCoy's 5A medium containing 10% fetal bovine serum (FBS), blasticidin and penicillin / streptomycin. After overnight incubation of cells, cell medium was removed and Opti-MEM medium without FBS was added. Cells were then treated with peptides for 4 / 16 h in Opti-MEM with either 10% FBS or serum-free. The final concentration of DMSO was 0.5%. Lactate dehydrogenase release was detected using the CytoTox-ONE Homogenous Membrane Integrity Assay Kit (Promega) according to the manufacturer's instructions. Measurements were performed using a Tecan plate reader. Maximum LDH release was defined as the amount of released LDH induced by the lytic peptide (iDNA79) and was used to normalize the results.

[0146] Tetracycline β-lactamase reporter gene assay (counterscanning) Jump-In™ T-REx™ is based on CHO-K1 BLA cells and contains stably integrated β-lactamase under the control of an inducible CMV promoter. Cells were seeded at a density of 4000 cells / well in 384-well plates. Cells were maintained in Dulbecco's Minimal Eagle Medium (DMEM) containing 10% fetal bovine serum (FBS), blasticidin and penicillin / streptomycin. After incubating cells for 24 h, cell medium was removed and replaced with Opti-MEM containing either 10% FBS or 0% FBS. Peptides were then dispensed into each well using a liquid handler, ECHO 555, and incubated for 4 / 16 h. The final working concentration of DMSO was 0.5%. β-lactamase activity was detected using ToxBLAzer Dual Screen (Invitrogen) according to the manufacturer's instructions. Measurements were performed using an Envision multiplate reader (Perkin-Elmer). Counterscreen activity was defined as the amount of β-lactamase activity induced by tetracycline.

[0147] HCT-116 Western blot analysis Preparation of compound stock and working solutions: 10 mM or 1 mM stock solutions of compounds were prepared in 100% DMSO. Each compound was then serially diluted in 100% DMSO and further diluted 10-fold with HPLC-grade sterile water to prepare 10x working solutions of each compound in 10% DMSO / water. Depending on the required volume used in the relevant assay, compounds were added to obtain the final concentrations as shown in the relevant figures with a residual DMSO concentration of 1% v / v.

[0148] HCT116 cells (Thermo Fisher Scientific) were cultured in DMEM cell medium supplemented with 10% fetal bovine serum (FBS) and penicillin / streptomycin. All cell lines were maintained in a 37°C humidified incubator with a 5% CO2 atmosphere. HCT116 cells were seeded in 96-well plates at a cell density of 60,000 cells / well and incubated overnight. Cells were further maintained in DMEM cell medium with 10% fetal bovine serum (FBS) and penicillin / streptomycin. Cell medium was then removed and replaced with cell medium containing various compounds / vehicle controls at the indicated concentrations in DMEM cell medium with 2% FCS. After the indicated incubation times (4 or 24 hours), cells were rinsed with PBS and then harvested in 100 μl of 1× NuPAGE LDS sample buffer (NP0008) supplied by Invitrogen. Samples were then sonicated, heated to 90°C for 5 min, sonicated twice for 10 s, and centrifuged at 13,000 rpm for 5 min. Protein concentration was measured by BCA assay (Pierce). Samples were separated on Tris-glycine 4-20% gradient gels (BIORAD) according to the manufacturer's protocol. Western blot transfer was performed on Immuno-blot PVDF membranes (Bio-Rad) using the Trans-Blot Turbo system (BIORAD). Western blot staining was then performed using antibodies against actin (AC-15, Sigma) as a loading control, as well as p21 (118 mouse monoclonal), MDM2 (2A9 mouse monoclonal antibody), and p53 (DO-1 mouse monoclonal antibody).

[0149] [Example] [Example 1] Preparation of azido ATSP-7041 macrocycles with C-terminal extensions WO2020112868A describes a series of ATSP-7041 peptide analogs with the addition of several alanine residues (herein described as polyalanine tails) to the C-terminal tail. Previously, an azido-ATSP-7041 peptide was made with an S12A substitution resulting in a triple Ala sequence (3xA) C-terminus to the S5 staple position. This peptide (reference macrocycle 1) had activity of 339 nM (0% serum, 4 hours) and 847 nM (10% serum, 16 hours) in the p53 cell assay (Table 3). When the C-terminus was extended with three additional Ala residues to obtain the 6xA tail macrocycle 2, the cellular activity was improved by about 3.5-fold both at 0% serum for 4 hours and at 10% serum for 16 hours. Macrocycle 3, containing a 5×A-dA tail, was also made and it behaved similarly to macrocycle 2 in cellular assays, with improved solubility compared to the benchmark macrocycle 1 (Tables 3 and 4).

[0150] [Example 2] C-terminal tail modification improves cellular uptake in 0% serum The C-terminal tail offers an opportunity to further enhance cellular potency by optimizing the C-terminal tail sequence. Examination of the helical wheel (Figure 2) revealed that placement of apolar residues at positions 14 and / or 17 could enhance MDM2 binding. Molecular modeling suggested that placing one or more phenylalanines at these positions could improve MDM2 binding and other properties (Figure 3).

[0151] A series of peptides (macrocycles 4-8) were generated in which one or more Phe residues were placed at positions 14 and / or 17, including the use of alpha methylation (see Table 1 for amino acid sequences). Placement of non-polar residues at these positions further enhanced MDM2 binding. Such macrocycles also showed enhanced or equivalent cellular activity compared to macrocycles 2 and 3 in a 0% FBS (serum), 4-hour assay (e.g., 143 nM for macrocycle 2 vs. 36 nM for macrocycle 4).

[0152] [Example 3] Placing a charged residue at position 16 improves properties In general, macrocycles 4-8 showed increased hydrophobicity as indicated by their higher AlogP98 and / or HPLC LogD (Tables 3 and 4). Here, it was found that placing a charged residue at position 16 further improved solubility and cellular potency while maintaining MDM2 binding. For example, macrocycle 9 was created with alpha-methylglutamic acid at this position, which showed improved cellular potency at 16 h, 10% conditions compared to macrocycle 4 (Table 3). It also showed improved solubility of 153 uM compared to macrocycles 5 and 7, which are close analogs of macrocycle 4. Macrocycle 9 also showed improved cellular potency at 16 h, 10% conditions compared to macrocycle 2. Thus, it is shown that the cellular activity and solubility of crosslinked peptidomimetic macrocycles can be improved by modifications at the C-terminal tail as disclosed herein.

[0153] [Example 4] Introduction of amphiphilic residues into the tail improves physicochemical properties It has been found that the introduction of amphiphilicity at the C-terminal tail can result in clean "drug"-like compounds with improved solubility and other properties. For example, glutamic acid or gamma-carboxyglutamic acid was discretely introduced into the tails of macrocycles 2 or 3 to obtain macrocycles 10 and 11. Macrocycle 10, with glutamic acid at position 14, showed improved cellular activity compared to macrocycle 3 at 16 h in 10% serum. Molecular modeling suggests that glutamic acid at position 14 may engage MDM2 arginine, Arg97 (Figure 4). Macrocycle 11, with carboxyglutamic acid (Gla) at position 12, showed improved binding compared to macrocycle 2, and approximately double the cellular activity at 527 nM at 10% serum for 16 h (Table 3). Both macrocycles 10 and 11 show excellent solubility (Table 4).

[0154] Macrocycles 10 and 11 were also profiled in cell proliferation assays in combination with macrocycle 2 (Table 5). Macrocycle 10 showed approximately two-fold improved cellular potency in the HTC116 p53 positive control cell line, at 187 nM, compared to macrocycle 3 at 420 nM. Macrocycle 11 showed approximately up to two-fold cellular activity over macrocycle 3.

[0155] Furthermore, both macrocycles 10 and 11 were clear without any burden (EC > 50uM at highest concentration) compared to macrocycle 2, which showed some residual activity at the highest assay concentration (29% inhibition at 50uM) in the p53 null negative control cell line. 50 , -18% inhibition). Macrocycles 10 and 11 therefore highlight the applicability of various modifications in the C-terminal tail to obtain compounds with improved cellular activity in cellular and / or counterscreening assays.

[0156] [Example 5] Using a bisalkyne instead of an alkene staple improved potency in cell proliferation assays Macrocycle 12 was generated containing bis-alkyne substitutions and a polyalanine C-terminal tail. This macrocycle showed comparable cellular activity (within 2-fold) compared to macrocycle 3 in both 0% and 10% serum (Table 3). It also showed comparable solubility (Table 4). Most strikingly, it improved cellular potency by over 3-fold to 124 nM compared to macrocycle 3 at 420 nM in the cell-grown HTC116 p53 positive control cell line (Table 4). It was also completely clear in the p53 null negative control cell line (EC > 50 uM at the highest concentration). 50 and 3% inhibition).

[0157] A dialkyne motif introduced into the C-terminal tail of macrocycle 4 showed superior cellular activity at 0% serum for 4 h. A glutamic acid was also introduced at position 12 to balance the hydrophobicity and improve the amphipathicity and cellular activity profile in the counterscreen. The resulting macrocycle 13 showed comparable potency to macrocycle 4 at 0% serum for 4 h (51 nM versus 36 nM) and significantly improved potency compared to macrocycles 4 and 2 at 10% serum for 16 h (153 nM versus 237 nM and 749 nM, respectively). Macrocycle 13 also showed superior solubility at 167 uM. Most importantly, it improved cellular potency in the cell-grown HTC116 p53 positive control cell line by more than 15-fold compared to macrocycle 4 (73 nM versus 1215 nM, respectively) and more than 7-fold compared to macrocycle 2 (73 nM versus 570 nM, respectively) (Table 5).

[0158] Thus, the macrocycles disclosed herein demonstrate the applicability of various modifications to provide potent cellularly active and clean compounds. [Table 3] [Table 4] [Table 5] While the present invention has been described herein with reference to illustrated embodiments, it should be understood that the invention is not limited thereto. Those skilled in the art and with access to the teachings herein will recognize additional modifications and embodiments within the scope thereof. Accordingly, the present invention is limited only by the scope of the claims appended hereto.

Claims

1. A bridged peptidomimetic macrocycle comprising: R 1 -R 2 - Beta Ala-L-T-F-X 1 -E-Y-W-A-QR 3 -X 2 -Z 1 -Z 2 -Z 3 -Z 4 -Z 5 -Z 6 -R 4 (SEQ ID NO: 18) (I), wherein R 1 Acyl and C 1-12 alkyl, R 2 is a natural or unnatural L-amino acid residue, R 3 is an aliphatic natural or unnatural amino acid residue, R 4 -OH, -NH 2 and 1 to 3 L- or D-amino acid residues, said C-terminal tail being an acid or amide group; X 1 and X 2 each is independently an α-mono- or α,α-disubstituted non-natural L- or D-amino acid residue; 1 and X 2 are bridged via hydrocarbon bonds from their respective alpha carbons, Z 1 , Z 2 , Z 3 , Z 4 , Z 5 and Z 6 each of which is independently a natural or unnatural amino acid residue.

2. R 1 The bridged peptidomimetic macrocycle of claim 1 , wherein is acetyl.

3. R 2 2. The bridged peptidomimetic macrocycle of claim 1 , wherein is selected from a lysine residue and an azidolysine residue.

4. R 3 The bridged peptidomimetic macrocycle of claim 1 , wherein is a cyclobutylalanine residue.

5. R 4 But -NH 2 and an L- or D-amino acid residue, and the C-terminal tail is an amide.

6. X 1 and X 2 each is independently an α-mono- or α,α-disubstituted non-natural L- or D-amino acid residue; 1 and X 2 are bridged from their respective alpha carbons via alkene hydrocarbon bonds.

7. X 1 and X 2 each is independently an α-mono- or α,α-disubstituted non-natural L- or D-amino acid residue; 1 and X 2 are bridged from their respective alpha carbons via dialkyne hydrocarbon bonds.

8. X 1 and X 2 is independently selected from the group consisting of (R)-2-amino-2-methyldec-9-enoic acid and (S)-2-amino-2-methylhept-6-enoic acid; 1 and X 2 are bridged from their respective alpha carbons via alkene bonds.

9. X 1 and X 2 is independently selected from the group consisting of (R)-2-amino-2-methyloct-7-ynoic acid and (S)-2-amino-2-methylhept-6-ynoic acid; 1 and X 2 are bridged from their respective alpha carbons via dialkyne bonds.

10. Said Z 1 -Z 2 -Z 3 -Z 4 -Z 5 -Z 6 2. The bridged peptidomimetic macrocycle of claim 1, wherein the sequence is selected from AAFAAF (SEQ ID NO:16), AAFA(alpha-Me-Glu)F (SEQ ID NO:19), AAEAA(D-Ala) (SEQ ID NO:20), EAFAAF (SEQ ID NO:21), AAAAA (SEQ ID NO:28) and AAAAA(D-Ala) (SEQ ID NO:22).

11. Said Z 1 -Z 2 -Z 3 -Z 4 -Z 5 -Z 6 The sequence is selected from AAFAAF (SEQ ID NO: 16), AAFA(alpha-Me-Glu)F (SEQ ID NO: 19), EAFAAF (SEQ ID NO: 21) and AAAAA(D-Ala) (SEQ ID NO: 22), The bridged peptidomimetic macrocycle of claim 10.

12. R 1 is acetyl, R 2 is selected from a lysine residue and an azidolysine residue; R 3 is a cyclobutylalanine residue, R 4 But -NH 2 and X 1 and X 2 each is independently an α-mono- or α,α-disubstituted non-natural L- or D-amino acid residue; 1 and X 2 are bridged from their respective alpha carbons via alkene or dialkyne hydrocarbon bonds; Said Z 1 -Z 2 -Z 3 -Z 4 -Z 5 -Z 6 The sequence is selected from AAFAAF (SEQ ID NO:16), AAFA(alpha-Me-Glu)F (SEQ ID NO:19), AAAAA(D-Ala) (SEQ ID NO:20), EAFAAF (SEQ ID NO:21), AAAAAAA (SEQ ID NO:28) and AAAAA(D-Ala) (SEQ ID NO:22), The bridged peptidomimetic macrocycle of claim 1.

13. R 1 is acetyl, R 2 is selected from a lysine residue and an azidolysine residue; R 3 is a cyclobutylalanine residue, R 4 But -NH 2 and X 1 and X 2 is independently selected from the group consisting of (R)-2-amino-2-methyldec-9-enoic acid and (S)-2-amino-2-methylhept-6-enoic acid; 1 and X 2 are bridged from their respective alpha carbons via alkene bonds, Said Z 1 -Z 2 -Z 3 -Z 4 -Z 5 -Z 6 The sequence is selected from AAFAAF (SEQ ID NO: 16), AAFA(alpha-Me-Glu)F (SEQ ID NO: 19), EAFAAF (SEQ ID NO: 21) and AAAAA(D-Ala) (SEQ ID NO: 22), The bridged peptidomimetic macrocycle of claim 1.

14. R 1 is acetyl, R 2 is selected from a lysine residue and an azidolysine residue; R 3 is a cyclobutylalanine residue, R 4 But -NH 2 and X 1 and X 2 is independently selected from the group consisting of (R)-2-amino-2-methyloct-7-ynoic acid and (S)-2-amino-2-methylhept-6-ynoic acid; 1 and X 2 are bridged from their respective alpha carbons via dialkyne bonds, Said Z 1 -Z 2 -Z 3 -Z 4 -Z 5 -Z 6 The sequence is selected from AAFAAF (SEQ ID NO: 16), AAFA(alpha-Me-Glu)F (SEQ ID NO: 19), EAFAAF (SEQ ID NO: 21) and AAAAA(D-Ala) (SEQ ID NO: 22), The bridged peptidomimetic macrocycle of claim 1.

15. The bridged peptidomimetic macrocycle of claim 1 having the formula (IV). 【Chemistry 1】

16. 2. The bridged peptidomimetic macrocycle of claim 1 having the formula (IX): 【Chemistry 2】

17. The bridged peptidomimetic macrocycle of claim 1 having the formula (X): 【Chemistry 3】

18. 2. The bridged peptidomimetic macrocycle of claim 1 having the formula (XIII): 【Chemistry 10】

19. 2. The bridged peptidomimetic macrocycle of claim 1, wherein the peptidomimetic macrocycle binds both MDM2 and MDMX, is cell-permeable without detectable cell membrane disruption as measured by a lactate dehydrogenase (LDH) release assay, and activates p53 intracellularly.

20. A pharmaceutical composition comprising the bridged peptidomimetic macrocycle of any one of claims 1 to 19 and a pharma- ceutically acceptable carrier or excipient.

21. 20. A method of treating cancer in a subject, comprising administering to the subject a bridged peptidomimetic macrocycle according to any one of claims 1 to 19.

22. 22. The method of claim 21, wherein the cancer is selected from melanoma, non-small cell lung cancer, head and neck cancer, urothelial cancer, breast cancer, gastrointestinal cancer, multiple myeloma, hepatocellular carcinoma, non-Hodgkin's lymphoma, renal cancer, Hodgkin's lymphoma, mesothelioma, ovarian cancer, small cell lung cancer, esophageal cancer, anal cancer, biliary tract cancer, colorectal cancer, cervical cancer, thyroid cancer, salivary gland cancer, pancreatic cancer, bronchial cancer, prostate cancer, pancreatic cancer, gastric cancer, ovarian cancer, bladder cancer, brain or central nervous system cancer, peripheral nervous system cancer, uterine or endometrial cancer, oral cavity or pharynx cancer, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, small intestine or appendix cancer, adrenal cancer, osteosarcoma, chondrosarcoma, and blood tissue cancer.

23. 21. A method of modulating the activity of p53 and / or MDM2 and / or MDMX in a subject, comprising administering to the subject a bridged peptidomimetic macrocycle according to any one of claims 1 to 19 or a composition according to claim 20.

24. 21. A method of antagonizing the interaction between p53 and MDM2 and / or between p53 and MDMX in a subject, comprising administering to the subject a bridged peptidomimetic macrocycle according to any one of claims 1 to 19 or a composition according to claim 20.

25. Use of a bridged peptidomimetic macrocycle according to any one of claims 1 to 19 for the preparation of a medicament for treating cancer.

26. 26. The use according to claim 25, wherein the cancer is selected from melanoma, non-small cell lung cancer, head and neck cancer, urothelial cancer, breast cancer, gastrointestinal cancer, multiple myeloma, hepatocellular carcinoma, non-Hodgkin's lymphoma, renal cancer, Hodgkin's lymphoma, mesothelioma, ovarian cancer, small cell lung cancer, esophageal cancer, anal cancer, biliary tract cancer, colorectal cancer, cervical cancer, thyroid cancer, salivary gland cancer, pancreatic cancer, bronchial cancer, prostate cancer, pancreatic cancer, gastric cancer, ovarian cancer, bladder cancer, brain or central nervous system cancer, peripheral nervous system cancer, uterine or endometrial cancer, oral cavity or pharynx cancer, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, small intestine or appendix cancer, adrenal cancer, osteosarcoma, chondrosarcoma, and cancer of the blood tissue.

27. The bridged peptidomimetic macrocycle of any one of claims 1 to 19 for treating cancer.

28. 28. The bridged peptidomimetic macrocycle of claim 27, wherein the cancer is selected from melanoma, non-small cell lung cancer, head and neck cancer, urothelial cancer, breast cancer, gastrointestinal cancer, multiple myeloma, hepatocellular carcinoma, non-Hodgkin's lymphoma, renal cancer, Hodgkin's lymphoma, mesothelioma, ovarian cancer, small cell lung cancer, esophageal cancer, anal cancer, biliary tract cancer, colorectal cancer, cervical cancer, thyroid cancer, salivary gland cancer, pancreatic cancer, bronchial cancer, prostate cancer, pancreatic cancer, gastric cancer, ovarian cancer, bladder cancer, brain or central nervous system cancer, peripheral nervous system cancer, uterine or endometrial cancer, oral cavity or pharynx cancer, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, small intestine or appendix cancer, adrenal gland cancer, osteosarcoma, chondrosarcoma, and cancer of the blood tissue.

29. 20. A combination therapy for treating cancer comprising administering to a subject a therapeutically effective amount of a bridged peptidomimetic macrocycle of any one of claims 1 to 19 and a therapeutically effective dose of a chemotherapeutic agent or radiation.

30. 30. The combination therapy of claim 29, wherein the chemotherapeutic agent or radiation is administered to the subject followed by the bridged peptidomimetic macrocycle, the peptidomimetic macrocycle is administered to the subject followed by the chemotherapeutic agent or radiation, or the chemotherapeutic agent or radiation is administered to the subject simultaneously with administration of the peptidomimetic macrocycle.

31. 20. A combination therapy for the treatment of cancer comprising a therapeutically effective amount of a bridged peptidomimetic macrocycle according to any one of claims 1 to 19 and a therapeutic dose of a chemotherapeutic agent or radiation.

32. The chemotherapeutic agent may be actinomycin, all-trans retinoic acid, alitretinoin, azacitidine, azathioprine, bexarotene, bleomycin, bortezomib, carmoful, carboplatin, capecitabine, cisplatin, chlorambucil, cyclophosphamide, cytarabine, dacarbazine, daunorubicin, docetaxel, doxifluridine, doxorubicin, epirubicin, epothilone, etoposide, fluorouracil, gemcitabine, hydroxyurea, idarubicin, imatinib, iki 32. The combination therapy of claim 29, 30 or 31, selected from sabepilone, irinotecan, mechlorethamine, melphalan, mercaptopurine, methotrexate, mitoxantrone, nitrosourea, oxaliplatin, paclitaxel, pemetrexed, romidopsin, tegafur, temozolomide (oral dacarbazine), teniposide, thioguanine, topotecan, utiderone, valrubicin, vemurafenib, vinblastine, vincristine, vindesine, vinorelbine, and vorinostat.

33. 20. A combination therapy for treating cancer, comprising administering to a subject a therapeutically effective amount of a bridged peptidomimetic macrocycle of any one of claims 1 to 19 and a therapeutically effective dose of a checkpoint inhibitor.

34. The combination therapy of claim 33, wherein the checkpoint inhibitor is an anti-PD1 antibody or an anti-PD-L1 antibody.

35. 35. The combination therapy of claim 34, wherein the therapy further comprises administering to the subject a therapeutically effective dose of a chemotherapeutic agent or radiation.

36. 20. The treatment of cancer comprising administering to a subject having said cancer a vector comprising a nucleic acid molecule encoding a wild-type p53 protein or a p53 variant having transcriptional activation activity, followed by one or more administrations of a therapeutically effective amount of a bridged peptidomimetic macrocycle according to any one of claims 1 to 19.

37. 37. The method of claim 36, wherein the vector is a plasmid, a retrovirus, an adenovirus or an adeno-associated virus.

38. 38. The treatment of claim 37, wherein the subject is administered chemotherapy or radiation therapy prior to administering the vector to the subject or after administering the vector to the subject.

39. 40. The treatment of any one of claims 36, 37, and 38, wherein the therapy further comprises administering a checkpoint inhibitor to the subject.

Citation Information

Patent Citations

  • Peptidomimetic macrocycles and uses thereof

    US20200289609A1

  • Peptidomimetic macrocycles

    WO2013123266A1

  • P53 activator peptidomimetic macrocycles

    WO2020257153A1